Biochemistry Of Hunk Kinase: Activation By Lkb1 And Identification Of First Substrates by Getchell, Samuel Eugene
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
2016
Biochemistry Of Hunk Kinase: Activation By Lkb1
And Identification Of First Substrates
Samuel Eugene Getchell
University of Pennsylvania, sgsg314@gmail.com
Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biochemistry Commons, and the Biology Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2303
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Getchell, Samuel Eugene, "Biochemistry Of Hunk Kinase: Activation By Lkb1 And Identification Of First Substrates" (2016). Publicly
Accessible Penn Dissertations. 2303.
https://repository.upenn.edu/edissertations/2303
Biochemistry Of Hunk Kinase: Activation By Lkb1 And Identification Of
First Substrates
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Biochemistry & Molecular Biophysics
First Advisor
Lewis A. Chodosh
Second Advisor
Michael Lampson
Keywords
AMPK-Related Kinase, DNA Damage Response, HUNK Kinase, LKB1
Subject Categories
Biochemistry | Biology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2303
  
BIOCHEMISTRY OF HUNK KINASE: ACTIVATION BY LKB1 AND 
IDENTIFICATION OF FIRST SUBSTRATES 
by 
Samuel E. Getchell 
 
A DISSERTATION 
in 
Biochemistry and Molecular Biophysics 
Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
2016 
 
Supervisor of Dissertation 
____________________________  
Lewis A. Chodosh  
Professor of Cancer Biology  
      
Graduate Group Chairperson    
______________________________ 
Kim A. Sharp 
Chair, Biochemistry and Molecular 
Biophysics Graduate Group 
Dissertation Committee  
Associate Professor Michael Lampson  
Assistant Professor Joseph Baur 
Associate Professor Eric Brown 
Professor Mitchell Lewis
  
BIOCHEMISTRY OF HUNK KINASE: ACTIVATION BY LKB1 AND 
IDENTIFICATION OF FIRST SUBSTRATES 
COPYRIGHT 
2016 
Samuel E. Getchell 
 
This work is licensed under the  
Creative Commons Attribution- 
NonCommercial-ShareAlike 3.0 
License 
 
To view a copy of this license, visit 
https://creativecommons.org/licenses/by-nc-sa/3.0/us/    
 
P a g e  | iii 
 
 
Dedication 
 
This thesis is dedicated to Catherine Getchell.  
P a g e  | iv 
 
 
ABSTRACT 
 
BIOCHEMISTRY OF HUNK KINASE: ACTIVATION BY LKB1 AND 
IDENTIFICATION OF FIRST SUBSTRATES 
Samuel E. Getchell 
Lewis A. Chodosh 
Protein phosphorylation is the most common form of reversible post-translational 
modification1.  Phosphorylation is controlled by at least 518 different kinases and at least 
156 different phosphatases, meaning that over 2% of the human genome is dedicated to 
managing phosphorylation2,3.  The two major protein kinase types are specific for either 
serine/threonine residues or tyrosine residues, though there are a number of dual 
specificity kinases that can phosphorylate serine, threonine, and tyrosine residues4.  
Signal transduction networks using phosphorylation regulate nearly every aspect of 
cellular function, and alterations to the activity of kinases and phosphatases underlies 
many human diseases, with cancer being a prominent example5.   
HUNK (Hormonally Up-regulated Neu-associated Kinase) is a protein kinase 
associated with aggressive subsets of human cancer and required for efficient 
tumorigenesis, metastasis, and tumor cell survival in several genetically engineered 
mouse models of cancer6–8.  HUNK is a member of the AMPK (5' Adenosine 
Monophosphate-activated Protein Kinase) subfamily of serine/threonine directed kinases, 
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collectively known as the AMPK Related Kinases (ARKs).  Fourteen out of seventeen of 
the ARKs are phosphorylated and activated by LKB1 (Liver Kinase B1), also known as 
Serine/Threonine Kinase 11 (STK11)9,10.  We provide evidence below that LKB1 
regulates HUNK in the same manner, phosphorylating a conserved threonine residue in 
the T-Loop of HUNK and increasing its activity as measured both by 
autophosphorylation and by substrate phosphorylation.  This suggests that HUNK is 
potential effector for LKB1 dependent phenotypes. 
We also sought to elucidate mechanisms of HUNK-dependent signal transduction 
by identifying substrates of HUNK kinase using a kinase assay on protein microarrays.  
We generated a ranked list of candidate substrates, and confirmed that both CHK2 and 
CAMKKβ are phosphorylated by HUNK.  We further provide preliminary data consistent 
with role for HUNK in the activation of the ATM/CHK2 pathway in response to DNA 
damage.  These data support the view of HUNK as a valuable therapeutic target in human 
cancer. 
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CHAPTER 1: INTRODUCTION 
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Published work from our lab indicates that HUNK is a viable therapeutic target in 
several human cancers wherein it serves to promote tumorigenesis, metastasis, and tumor 
cell survival.  To better understand the molecular interactions regulating these 
phenotypes, we conducted experiments to show that LKB1 phosphorylates and activates 
HUNK, indicating HUNK is a potential effector for LKB1 dependent pathways.  We 
therefore begin with a brief review of HUNK, LKB1, and the LKB1 regulated kinases 
collectively known as the ARKs. 
 
HUNK kinase. 
HUNK is a member of the SNF1 family of serine/threonine kinases, also known 
as the AMPK-Related Kinases, and was initially identified in a mammary epithelial cell 
line derived from a tumor that arose in an MMTV-neu transgenic mouse 11.  Subsequent 
work in mice revealed that HUNK is located on distal mouse chromosome 16, is 
transcribed into 5.1 and 5.6 kb mRNA species, and encodes an 80-kDa protein of 714 
amino acids12.  HUNK expression is both temporally regulated during murine 
development and spatially regulated within a variety of tissues, suggesting multiple 
potential roles in the developing and adult organism12. 
HUNK appears to play a role in hormone induced changes in the mammary gland 
as its expression is induced by the steroid hormones 17β-estradiol and progesterone with 
peak expression at day 7 of pregnancy, expression nearly absent during lactation, and 
higher again during involution13.  Consistent with the hypothesis that HUNK controls 
mammary gland development during pregnancy, mice engineered to overexpress HUNK 
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in the mammary epithelium show defects in both differentiation and proliferation of these 
tissues13. 
Multiple lines of evidence implicate HUNK in promoting the development and 
progression of cancers in a variety of contexts.  For example, HUNK expression is 
significantly higher in aggressive subsets of human cancers, including lymph node 
positive breast cancers, HER2-amplified breast cancers, and poorly differentiated cancers 
of the breast, ovary, and colon6.  Consistent with a functional role for HUNK in 
tumorigenesis, HUNK is required for primary mammary tumor formation in mouse 
models of breast cancer driven by HER2/neu overexpression or PTEN deletion7,8, and 
HUNK expression and kinase activity are required for the metastasis of mammary tumors 
driven by c-MYC6.   
While the precise molecular mechanisms controlling HUNK-dependent 
phenotypes are unknown, several mechanistic details are known.  HUNK suppresses 
apoptosis in mouse models of cancer driven by HER2/neu overexpression or PTEN 
deletion7,8, in the former by negative regulation of p27kip1 expression and nuclear 
localization and in the latter by negative regulation of c-Myc expression.  HUNK 
expression is required in HER2-positive human cancer cell lines for full activation of 
autophagy and JNK kinase signaling14,15.  Inhibition of HER2/neu or PI3K/Akt activity 
down-regulates HUNK expression7.  Work performed in the Korobko lab suggests that 
the kinase domain and the UBA are required to localize a portion of cellular HUNK to 
the plasma membrane in a variety of cell lines and in yeast16. 
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While several mechanistic details of HUNK-dependent pheontypes are known, 
the work described herein is the first to characterize immediate molecular interactions, in 
particular activation of HUNK by LKB1 and identification of substrates of HUNK.  
HUNK is a member of the AMPK (5' Adenosine Monophosphate-activated Protein 
Kinase) subfamily of kinases, and as members of this subfamily are activated by LKB1 
phosphorylation of a conserved threonine residue in their T-Loops, we investigated 
whether HUNK was also regulated in this manner. 
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Figure 1.  Model of LKB1 activation of and binding to HUNK.  Arrows indicate 
phosphorylation, green indicates activation.  Dotted line indicates binding.  (A) The 
LKB1 heterotrimer, consisting of LKB1, MO25, and STRAD, phosphorylates HUNK on 
multiple sites, with phosphorylation at T222 of HUNK resulting in increased HUNK 
kinase activity.  HUNK then autophosphorylates at a number of sites and phosphorylates 
substrates.  (B) HUNK binds to complexes of LKB1 that contain STRADβ but not 
STRADα.  STRADβ containing complexes localize primarily to the nucleus, while 
STRADα complexes are primarily cytoplasmic, and HUNK localizes to both the nucleus 
and the cytoplasm.  
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LKB1 and Peutz-Jeghers syndrome. 
LKB1 was first identified in 1998 as the gene whose germline mutation and 
inactivation results in Peutz-Jeghers syndrome (PJS)17,18.  The first report of a patient 
bearing one of the syndrome’s most obvious symptoms was probably made in 1896 by 
the British surgeon Jonathan Hutchinson, who reported identical twins with spots on and 
around the lips and mouth19.  The connection between polyps and spots was made in 
1921 in a published case report by the Dutch internist Johannes Laurentius Augustinus 
Peutz20.  PJS was formally recognized as a syndrome with autosomal dominant 
inheritance in 1949 by the American internist Harold Joseph Jeghers21.  The National 
Institutes of Health (NIH) estimates the frequency of PJS as 1 in 25,000 to 300,00022. 
PJS patients manifest a range of symptoms.  The earliest presenting symptom can 
be dark freckles on and around the lips of a newborn.  Patients often present by age five 
with mucocutaneous pigmentation (small dark spots).  Other symptoms include clubbed 
fingers or toes, abdominal cramping, intestinal hamartomatous polyps, and intestinal 
intussusception (part of the intestine folded in on itself).  Repeated surgical intervention 
can be required to resolve intestinal blockage due to polyps or intussusception23,24.  
Perhaps the most clinically significant manifestation of PJS is an increased risk of 
a range of cancers.  A meta-analysis performed in 2010 found the lifetime relative risk of 
any type of cancer to be as much as 18 times higher than the general population25, with an 
increased risk of malignancies including small intestinal, gastric, pancreatic, colorectal, 
ovarian, lung, endometrial, and breast (see Table 1)17,18. 
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Table 1. Cumulative cancer risks (approaching lifetime risks)
Age (years) Cumulative Risk
60-70 37-93%
60-70 38-66%
60-70 13-18%
Stomach 65 29%
Small bowel 65 13%
Colorectum 65 39%
Pancreas 65-70 11-36%
Lung 65-70 7-17%
Breast 65-70 32-54%
Uterus 65 9%
Ovary 65 21%
Cervix 65 10%
Testes 65 9%
Adapted from van Lier et al., 2010, Am J Gastroenterol.
Site
Any cancer
Gastrointestinal cancer
Gynecological cancer
Per origin
 
In 1997, Hemminki et al. discovered a genetic susceptibility locus for PJS at 
chromosome 19p26.  In 1998, Hemminki et al. and Jenne et al. independently reported 
that LKB1 is the gene mutated in PJS17,18.  Germline mutation of LKB1 is found in 66-
94% of PJS patients27–29, and no mutations in LKB1-interacting proteins were found in 
two genetic screens of PJS patients30,31, suggesting that loss of LKB1 function accounts 
for nearly if not all cases of PJS. 
 
LKB1 and tumor suppression. 
Evidence for the tumor suppressive role of LKB1 extends beyond the increased 
risk of cancer is in PJS patients.  Consistent with LKB1’s identification as a bona fide 
tumor suppressor, somatic mutation or deletion of LKB1 (STK11) occurs in 15-20% of 
lung adenocarcinomas and in 1-10% of cancers of the ovary, bladder, cervix, pancreas, 
esophagus, stomach, thyroid, colon and breast32–39.  Examination of data from The 
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Cancer Genome Atlas (TCGA) reveals that LKB1 is the third most commonly mutated 
gene in human lung adenocarcinoma (ADC)33. 
In 1999, LKB1 expression was reintroduced in several LKB1-deficient tumor cell 
lines, which induced a G1 cell cycle arrest without altering apoptosis40,41.  In at least one 
cell line (SW13 adrenal carcinoma cell line), LKB1 physically associated with BRG1 and 
LKB1 expression, but not kinase activity, was demonstrated to be necessary for BRG1-
induced growth arrest42. 
 
Regulation of LKB1. 
LKB1 expression is at least partially controlled by the miR-17∼92 microRNA 
cluster, which is itself a direct transcriptional target of Myc43,44.  Suppression of LKB1 by 
miR-17 relieves mTORC1 inhibition by AMPK, promoting metabolic reprogramming 
and lymphomagenesis in animal models45.  Consistent with this, miR-17~92 expression is 
elevated in cancers of the colon45, lung46, and DLBCL47. 
LKB1 activity is controlled primarily by complex formation, as it is inactive 
unless in a complex with the scaffold protein MO25 (mouse protein 25) and the 
pseudokinase STRAD (STE20-Related Kinase Adaptor)48,49.  LKB1 does not require 
phosphorylation of its T-Loop in order to be activated by binding to MO25/STRAD50.  
MO25 and STRAD each have two principal isoforms, alpha and beta.  These MO25 
isoforms are 80% conserved at the amino acid level, while STRAD isoforms are only 
42% conserved and STRADα has two nuclear export sequences (NES) that are lacking in 
STRADβ (Figure 2). 
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While MO25 isoforms serve the same function, the alpha isoform has a slightly 
greater ability to activate LKB1, which is attributable to stabilization of the ternary 
complex by MO2550.  The differences between the STRAD isoforms have been largely 
neglected in the literature, despite evidence in 2008 showing that STRADα, but not 
STRADβ, can effectively localize active LKB1 to the cytoplasm where it can activate 
AMPK51.  Kinase-deficient mutants of LKB1 localize predominantly to the nucleus40.  
LKB1 is shuttled into the nucleus by direct interaction with importins-α/β, and LKB1 is 
exported from the nucleus through its interaction with STRADα, which binds CRM7 and 
Exp751.  STRADα also inhibits binding of LKB1 to importins.  For STRAD, as with 
MO25, the alpha isoform has a greater ability to activate LKB110,49. 
Veleva-Rotse et al. demonstrated in 2014 that while either STRADα or STRADβ 
are sufficient to drive axon formation in the developing cortex, STRADα but not 
STRADβ is required in vivo for mutual stabilization of protein levels with LKB152.  This 
same group also established that the splice variant isoforms of STRADα are tissue 
specific and developmentally regulated, indicating a need for further study of the impact 
of STRAD isoforms on LKB1 signal transduction. 
Several post translational modifications (PTM) influence the localization of 
LKB1.  LKB1 can be deacetylated by SIRT1 and this correlates with an increase in 
activity and cytoplasmic localization in HEK293T cells, with the most important site for 
deacetylation being K48 in LKB153.  SIRT1 has also been shown to control LKB1 
activation in the HepG2 hepatocyte cell line54.  In an elegant murine system with whole 
body inducible knockout of SIRT1, SIRT1 is required for increased AMPK activation, 
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mitochondrial biogenesis and function, and increased NAD+ levels in skeletal muscle in 
mice treated with moderate doses of resveratrol55. 
LKB1 is regulated by modification with both ubiquitin and SUMO.  Skp2 
ubiquitination of LKB1 is required for robust formation of the LKB1 heterotrimer and 
oncogenic Ras-G12V activity markedly increases LKB1 activity in cells56.  Consistent 
with this, both Skp2 and LKB1 are overexpressed in hepatocelluar carcinoma (HCC) and 
high expression is predictive of reduced overall survival56.  Sumoylation of LKB1 at 
L178 is triggered by energy stress and is essential for promoting interaction with and 
activation of AMPK via a SUMO-interacting motif (SIM) in AMPK57. 
LKB1 has three isoforms, with the full length being the most abundantly 
expressed.  There is also a splice variant altered in the C-terminus that is expressed in 
sperm and required for spermiogenesis58.  The third isoform of LKB1 is catalytically 
inactive due to omission of a large portion of the N-terminus, but it potentiates AMPK 
activation by binding to the autoinhibitory domain (AID) of AMPK and, in some 
contexts, is oncogenic59. 
The orphan nuclear receptor Nur77 binds LKB1 in the nucleus, modestly 
decreasing its cytoplasmic/nuclear partitioning ratio and thereby reducing AMPK 
activation60.   
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Figure 2.  Amino acid conservation in LKB1 complex members MO25 and STRAD.   
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AMPK (5' Adenosine Monophosphate-activated Protein Kinase). 
Much of the growth suppression induced by LKB1 is mediated through its most 
studied substrate, AMPK.  Three independent groups reported in late 2003 and early 
2004 that LKB1 is the upstream activating kinase for AMPK49,61,62.   
AMPK is a key enzyme in the maintenance of cellular energy homeostasis.  
AMPK senses the lowering of cellular energy levels via the relative levels of ATP, ADP, 
and AMP (adenosine tri-, di-, and mono-phosphate).  When the cellular AMP:ATP ratio 
rises, AMPK is activated and phosphorylates a number of substrates to shift cellular 
activity from energy consuming to energy producing pathways63,64.  AMPK also regulates 
energy homeostasis at the level of the whole organism by influencing appetite and 
circadian rhythm64,65. 
AMPK inhibits lipid anabolism and promotes lipid catabolism, and promotes 
glucose uptake and glycolysis while inhibiting glycogen synthesis and gluconeogenesis66.  
AMPK inhibits protein synthesis through multiple mechanisms, including indirectly 
inhibiting mTORC1 by phosphorylating both TSC2 and raptor67.  AMPK can promote 
autophagy via direct and indirect mechanisms, which both provides additional energy to 
the cell and promotes the turnover of damaged mitochondria68.  AMPK promotes the 
cellular defense against reactive oxygen species (ROS) through both short and long term 
mechanisms69. 
According to the theory of the stress hallmarks of cancer, tumor cells undergo 
DNA damage and replication stress, proteotoxic stress, mitotic stress, metabolic stress, 
and oxidative stress70.  Early in tumorigenesis, when cells are exposed to increasing 
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levels of these stresses, AMPK is activated and limits growth of the tumor cells both by 
mechanisms mentioned above and by activation of p53 via Ser-15 phosphorylation, 
which then activates the CDKI p21CIP, leading to reversible arrest at the G1/S boundary71.  
Sustained activation of this checkpoint can lead to cellular senescence. 
More advanced tumors can evade checkpoint-induced arrest, continuing to 
proliferate under stress conditions72.  In these circumstances, AMPK can promote tumor 
cell survival by a variety of mechanisms.  AMPK activity promotes lung tumor cell 
survival during metabolic stress by maintaining NADPH homeostasis, allowing cells to 
buffer ROS69.  AMPK is active in human patient prostate cancer (PC) samples and is 
required for survival and proliferation of PC cell lines73.  AMPK inhibits cisplatin-
induced apoptosis in multiple tumor cell lines via both inhibition of mTORC1 and 
induction of autophagy74. 
AMPK functions as a heterotrimeric complex of one catalytic α subunit and one 
each of the regulatory β and γ subunits, and humans have two paralogs for α and β and 
three isoforms for γ75.  This gives twelve possible subunit configurations, and evidence 
exists suggesting that the different complexes have different function and regulation76.  
After complex formation, AMPK activity is regulated by both allostery and 
phosphorylation of T172 in the α catalytic subunit.  ATP, ADP, and AMP bind 
competitively to the γ subunit, with AMP and, to a lesser extent, ADP allosterically 
protecting T172 of the catalytic α from dephosphorylation, thereby promoting its 
phosphorylation and activating AMPK ~10-fold 77. 
P a g e  | 14 
 
 
AMPK activity increases at least 100-fold upon phosphorylation of AMPKα at the 
T-Loop residue T17278.  While LKB1 is the major upstream activating kinase, 
phosphorylation of AMPKα at T172 is regulated by at least three kinases and three 
phosphatases: LKB1, Ca2+/calmodulin-dependent protein kinase kinase-beta 
(CAMKKβ), TGFβ-activated kinase 1 (TAK1); protein phosphatase 2A (PP2A); protein 
phosphatase 2C (PP2C) and Mg2+-/Mn2+-dependent protein phosphatase 1E 
(PPM1E)77,79–84. 
 
LKB1 and the ARKs. 
Beyond its regulation of AMPK, LKB1 regulates cellular metabolism, polarity, 
and proliferation by activating a group of kinases collectively referred to as the AMPK-
related kinases (ARKs).  These kinases share a common domain structure with an N-
terminal kinase domain, followed by a UBA (ubiquitin-associated) domain in all save the 
AMPKs and NUAKs.  The MARKs possess a KA1 (Kinase Associated 1) domain that 
binds acidic phospholipids.  AMPKs are the only ARKs activated by stimuli such as 
AICAR, phenformin, or increased cellular AMP9.  All ARKs are activated 
phosphorylation of a conserved threonine on their T-Loop.  NIM1 and MELK can 
autophosphorylate, whereas LKB1 activates the other 15 family members.  MARK1-3 
also are phosphorylated by LKB1 on a serine 4 residues C-terminal to the conserved 
threonine.  AMPK is also activated by two other kinases that phosphorylate the conserved 
threonine, TAK1 (TGFβ-activated kinase 1) and CAMKKβ79,81,82. 
P a g e  | 15 
 
 
The UBAs of the ARKs fold into three-helix bundles that weakly interact with 
ubiquitin or polyubiquitin chains85.  There is sequence homology between the UBAs of 
the ARKs and the AID (autoinhibitory domain) of AMPK86.  Mutation of a key residue in 
the UBA has been shown to abrogate activation by LKB186.  Crystal structures and 
kinase assays of MARK1 and MARK2 show that the UBA can bind directly to the 
catalytic domain and inhibit kinase activity86, though NMR studies show that the 
MARK3 UBA is highly dynamic and exists in a rapid unfolding/refolding equilibrium87. 
The ARKs are polyubiquitinated by unusual Lys-29 and Lys-33-linked chains, 
and MARK4 and NUAK2 are clients of the deubiquitinase USP9X, which removes 
polyubiquitin and allows activation by LKB188.  The 14-3-3 family of scaffolding 
proteins also bind to at least the MARK and SIK kinases, anchoring them in the 
cytoplasm without otherwise affecting kinase activity89–91. 
 
BRSK/SAD Kinase (Brain-Specific Serine/Threonine-Protein Kinase, Synapses of 
Amphids Defective Homolog). 
SAD kinases have expression in a range of tissues with highest levels in the 
brain92.  There are two main paralogs of the protein, BRSK1/SAD-A and BRSK2/SAD-
B.  One of the best studied functions of BRSK is the regulation of polarization of 
neurons93.  SAD-A/B kinases regulate multiple steps in neuronal development and 
differentiation, including axon specifications and maturation in both the central and 
peripheral nervous system94.  Consistent with this, SAD-B dependent regulation of 
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vesicular trafficking and vesicular release probability at pre-synaptic terminals in the 
hippocampus is required for contextual fear learning in mice94. 
SAD kinases also have important functions in the regulation of cell division and 
DNA damage.  SAD-B phosphorylation of γ-tubulin at Ser-131 regulates centrosome 
duplication via control of CP110 affinity for nascent centrioles, where CP110 forms a 
cap, terminating growth of the centriole and seeding growth of centriolar microtubules95.  
Phosphomimetic mutation of γ-tubulin (S131D) increased centrosome numbers and 
phospho-ablative (S131A) mutation impaired centrosome duplication95.  SAD-B localizes 
to chromatin and centrosomes and promotes the nuclear localization of γ-tubulin by 
phosphorylation of Ser-385 in a manner enhanced by the SAD-B phosphorylation of γ-
tubulin at Ser-13196.  While the link between impaired centrosome duplication and cancer 
is established97, the link between SAD kinase control of centrosome duplication and 
cancer risk in PJS patients is largely unexplored. 
DNA damage induced by UV, but not γ-IR, increases kinase activity of SAD-A 
and induces it to translocate to the nucleus in A172 cells92.  Overexpression of SAD-A in 
HeLa cells causes arrest at G2/M, and knockdown of SAD-A by siRNA reduces UV-
induced G2/M arrest92. 
Regulation of SAD kinases is incompletely understood.  LKB1 activation of SAD 
kinases has been demonstrated both in vitro and in vivo.  While CAMKKα has been 
shown to activate SAD-A in vitro and when overexpressed in cells98, there is also 
evidence that BRSK activity in the distal region of axons in polarized hippocampal 
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neurons does not respond to Ca2+, indicating at least one setting in which CAMKK may 
not activate BRSK in vivo99. 
Expression of SAD kinases is promoted by mTORC1100. The SAD/BRSK kinases 
have a mode of autoinhibition thought to be unique to the ARKs in which an 
autoinhibitory sequence (AIS) binds to the junction between the kinase domain and the 
UBA (ubiquitin-associated domain), stabilizing an inactive conformation of the kinase101.  
The AIS and the KA1 (kinase associated-1) domain cooperate to bind to phospholipids, 
resulting in at least partial activation of kinase activity101. 
 
MARK/Par-1 kinases (Microtubule Affinity Regulating Kinase 1/Partition-
defective-1c, MARK2/Par-1b, MARK3/Par-1a/C-TAK1/p78, MARK4/Par-1d). 
MARK1/PAR-1 was initially identified in a screen to identify regulators of early 
embryonic polarity in Caenorhabditis elegans102.  This screen also identified the C. 
elegans homolog to LKB1 as PAR-4.  Subsequent studies showed that Par-1 is one of 
several proteins conserved from yeast to humans required for cellular polarity, including 
Par-3/ASIP, Par-4/LKB1, Par-5/14-3-3, Par-6, and aPKC/PKC-3103–113. 
Drewes et al. showed in 1997 that MARK1 and MARK2 phosphorylate 
microtubule associated proteins (MAPs) MAP2, MAP4, and Tau, at the KXGS motif114.  
Tau functions to stabilize microtubules115 and MARK phosphorylation of Tau reduces its 
affinity for microtubules, destabilizing them114.  Ectopic expression of MARKs in CHO 
cells is sufficient to destabilize the microtubule cytoskeleton114.  Tau is 
hyperphosphorylated at the KXGS motifs in Alzheimer’s disease, leading to formation of 
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multiple toxic species of Tao aggregates, with Tau phosphorylated by at least Akt, GSK-
3β, and MARK2116. 
MARK3/p78/C-TAK1 was first implicated in control of cell proliferation when its 
loss was associated with transformation of pancreatic cells by treatment with known 
carcinogens117.  Entry into mitosis is triggered by activity of CDC2/cyclin B complex, 
which is activated by CDC25C118.  MARK3 prevents mistimed CDC25C activity by 
phosphorylating Ser-216 during interphase, promoting binding to 14-3-3 and 
sequestration in the cytoplasm of CDC25C118,119.  Ser-216 of CDC25C is also 
phosphorylated by CHK1 and CHK2 in response to DNA damage, preventing the 
crossing of the G2/M checkpoint120. 
MARK kinases also control cell proliferation through modulation of Ras 
signaling.  MARK3 regulates Ras signaling by phosphorylating the motif for 14-3-3 
binding to KSR1, preventing improper pathway activation by sequestering MEK from 
Raf121,122.  KSR1 has also been implicated as a tumor suppressor in breast cancer via 
patient expression data and overexpression experiments in mice, where KSR1 was found 
to stabilize BRCA1 protein levels123. 
In a paper with implications for PJS patients and cancer susceptibility, Mohseni et 
al. showed that LKB1-MARK signaling antagonizes YAP nuclear localization as 
demonstrated by increased nuclear YAP in LS174T-W4 cells with siRNA against 
MARK4124.  Furthermore, they also proved that YAP activity is enhanced in several 
LKB1-deficient tumor types and in PJS patient polyps, breast adenocarcinoma, and liver 
adenocarcinoma.  YAP activity is sufficient to overcome LKB1-driven tumor 
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suppression, and YAP is required for efficient growth of LKB1-mutant tumors and 
tissues.  These data in total suggest that YAP dependence is a promising therapeutic 
target in LKB1-deficient tumors. 
The MARK kinases possess a KA1 domain (Kinase Associated-1) that serves to 
bind acidic phospholipids, particularly phosphatidylserine, thereby promoting membrane 
localization and relief of autoinhibition due to interaction between the C-terminal KA1 
domain and the kinase domain125.  The KA1 domain is not found in other ARKs.  MARK 
localization is also controlled by binding to 14-3-3 via multiple phosphosites, at least 
some of which are generated via autophosphorylation, anchoring MARKs in the 
cytosol91. 
 
Salt-Inducible Kinases (SIK1, SIK2/QIK, SIK3/QSK).   
One of the primary functions of SIKs is coupling the activity of the Na,K-ATPase 
(NK) with intracellular sodium concentration, allowing small increases in sodium to lead 
to corrective increases in NK activity, via SIK2 phosphorylation of PME-1, which 
associates with the NK α-subunit126.  SIK1 also regulates NK, controlling nuclear 
localization of cAMP-regulated transcriptional coactivators (CRTCs) to alter 
transcription of a number of genes including the β subunit of NK127. 
SIKs also signal through CRTCs to regulate metabolism at the level of the whole 
organism, constraining expression of genes required for gluconeogenesis and lipogenesis 
until SIKs are inactivated by PKA128.  Patel et al. took advantage of a highly specific pan-
SIK inhibitor to determine that the SIKs serve to inhibit gluconeogenesis in the liver, and 
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SIK2 phosphorylation in the liver is regulated by glucagon and not by insulin, significant 
because those hormones serve as the yin and yang (counter-regulatory hormones) to 
coordinate hepatic gluconeogenesis and peripheral glucose uptake129,130.   
SIK1 is required for p53-dependent anoikis and suppression of metastasis in 
immortalized human mammary epithelial cells (tHMEC) and low SIK1 expression levels 
predicts increased distal metastasis in human breast cancer131.  Consistent with this, SIK1 
inhibits migration of the gastrin responsive AGS-GR cell line
132. 
In addition to regulation by LKB1, SIKs are regulated by 14-3-3, which binds the 
phosphorylated form of the T-Loop of SIK1 and SIK3, enhancing cytoplasmic 
localization and increasing their kinase activity, likely through increased interaction with 
substrate90.  SIK1 expression in multiple adenocarcinoma cell lines is induced by the 
hormone gastrin and inhibited by ICER (inducible cAMP early repressor)132. 
 
LKB1 and non-ARK Substrates 
Evidence has been published that LKB1 phosphorylates at least three substrates 
that are not ARKs (Table 2).  Song et al. presented data showing that in cultured human 
umbilical vein endothelial cells, PKCζ phosphorylates LKB1 at Ser-428, inducing 
cytoplasmic localization of LKB1, which leads to phosphorylation of PTEN at Ser-380, 
Thr-382, and Thr-383, with in vitro evidence that LKB1 may directly phosphorylate 
PTEN133.  These phosphorylations activate PTEN, leading to inhibition of Akt. 
LKB1 inhibits PAK1 (p21-activated kinase) by phosphorylating Thr-109, which 
results in reduced binding to p21134.  It is worth noting that of the three putative non-
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ARK substrates of LKB1, this site is the only site with at least partial conservation with 
ARK sites, as PAK1 is partially conservative from -3 to +1 with the ARK sites 
phosphorylated by LKB1 (Table 2, Figure 2). 
Zeng et al. reported convincing data that LKB1 is recruited to the p21/WAF1 
promoter by p53 and recruitment of kinase active LKB1 is required for p53-dependent 
gene transcription135.  They also showed evidence that LKB1 can phosphorylate p53 at 
Ser-15 and Ser-392 in vitro, though whether phosphorylation of these sites is determined 
by direct action of LKB1 in vivo is less clear. 
 
Protein Gene Organism
MW                                    
(DA)
Site Site_+/-7_AA
S15 PSVEPPLSQETFSDL
S392 FKTEGPDSD______
PAK1 PAK1 human 60,647 T109 QWARLLQTSNITKSE
S380 EPDHYRYSDTTDSDP
T382 DHYRYSDTTDSDPEN
T383 HYRYSDTTDSDPENE
xxgxklxTfCGSpxYLKB1 Consensus Site
p53 TP53 human 43,653
PTEN PTEN human 47,166
 
Table 2.  LKB1 non-ARK Substrates 
 
DNA damage repair 
Recent work has uncovered links between LKB1 and the DNA damage response 
(DDR), revealing several contexts in which LKB1 is required for a robust cellular 
response to DNA damage. 
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Wang et al. showed that LKB1 is required for efficient HR-mediated 
reconstitution of a GFP reporter gene136.  Consistent with this finding, they also 
demonstrated that LKB1 deficiency delays repair (but not formation) of γIR-induced 
DNA damage as measured by γ-H2AX foci in multiple cancer cell lines.  Lastly, they 
showed that LKB1 deficiency increases cancer cell sensitivity to both cisplatin and PARP 
inhibitors.  While the mechanism of LKB1 regulation of DNA damage was largely 
uninvestigated in this work, they did show that LKB1 and ATM co-immunoprecipitate 
and colocalize with γ-H2AX foci in γ-IR treated cells.  ATM associates with LKB1, p53, 
and BRCA1 in response to DNA damage and point mutations in ATM between amino 
acids 91 and 97 ablate formation of these complexes, providing further evidence for a 
role for LKB1 in regulation of HR137.  Additional evidence for LKB1 regulation of the 
DDR comes from Gupta et al., who in 2015 determined that LKB1 reduces mutation rate 
and increases survival after DNA damage by stimulating BRCA1 expression in an at least 
partially AMPK-dependent manner138. 
Bungard et al. found evidence that AMPKα2 binds and phosphorylates histone 
H2B at S36 in response to cellular stress to increase transcription of known AMPK-
dependent stress response genes139.  In 2014, Ui et al. demonstrated that LKB1 controls 
BRM-dependent non-homologous end joining, and cells deficient for LKB1 exhibit 
marked increases in chromosomal aberrations140.  Notably, Ui et al. found that in cells 
deficient for AMPKα2, chromosomal aberrations increased only slightly, as opposed to 
the large increases in aberrations observed in cells deficient for LKB1.  There are at least  
two potential reasons for AMPKα2 deficiency failing to account for the full LKB1-
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dependent phenotype: compensation by AMPKα1 and the action of other effectors of 
LKB1. 
Esteve-Puig et al. have shown that LKB1 haploinsufficient mice exhibit 
dramatically increased sensitivity to UVB-induced skin cancer, and both these mice and 
LKB1-deficient human keratinocytes exhibit impaired repair of UVB-induced DNA 
damage141.  LKB1 dependent response to UV-induced DNA damage is at least partially 
dependent upon SAD1 kinase, as overexpression of SAD1 in HeLa cells causes arrest at 
G2/M, and knockdown of SAD1 by siRNA reduces UV-induced G2/M arrest 92.  DNA 
damage induced by UV but not γ-IR increases kinase activity of SAD1 and causes it to 
translocate to the nucleus in A172 cells92. 
In addition to controlling DNA damage repair, LKB1 also controls ROS-induced 
DNA damage via the p38 pathway142.  LKB1-dependent activation of the MKK3/6-p38 
cascade is required for protection against ROS-induced DNA damage and mutation and is 
independent of AMPK142.  LKB1 potentiates p38 signaling by maintaining the activity of 
the Cdc42-PAK1 (p21 activated kinase 1) complex, thereby increasing the activity and 
anti-oxidant effects of superoxide dismutase-2 and catalase142. 
While it is known that IR induces ATM phosphorylation of LKB1 at Thr-366 
(363 in human, 366 in mouse)143, it has been shown that LKB1 modified such that it 
cannot be phosphorylated at this residue due to alanine substitution (LKB1-T363A) is 
still localized to sites of DNA DSBs in an ATM/ATR-dependent fashion.  It is possible 
that phosphorylation of LKB1-T363 controls other aspects of LKB1 activity, but this has 
yet to be directly evaluated.  
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CHAPTER 2: IDENTIFICATION OF THE AMPK-RELATED KINASE HUNK AS A 
SUBSTRATE OF LKB1 
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ABSTRACT 
LKB1, also known as Serine/threonine kinase 11 (STK11), regulates energy 
homeostasis and multiple cellular functions related to carcinogenesis through its 
phosphorylation and activation of adenosine monophosphate-activated protein kinase 
(AMPK) and 14 AMPK related kinases (ARKs).  Two additional ARKs are reportedly 
not phosphorylated by LKB1 and the remaining ARK, HUNK (Hormonally Up-regulated 
Neu-associated Kinase), has been predicted based on sequence homology not to be a 
substrate for LKB1.  Classically described as a tumor suppressor, germline loss of LKB1 
causes Peutz-Jeghers syndrome, LKB1 is somatically mutated in a broad spectrum of 
human cancers, and LKB1-mediated activation of AMPK and ARKs maintains cell 
polarity and suppresses cell growth and proliferation.  More recent evidence suggests the 
existence of pro-tumorigenic roles for LKB1 in supporting tumor cell survival and 
proliferation, although the LKB1 substrates mediating these roles are unclear.  Here we 
demonstrate that, contrary to prediction, LKB1 phosphorylates and activates HUNK, a 
kinase that promotes carcinogenesis, metastasis, and tumor cell survival in a variety of 
biological contexts.  LKB1 activates HUNK by phosphorylation on a conserved threonine 
(T222) within the T-loop and is both sufficient and required for HUNK activation in 
vivo.  We further demonstrate that HUNK forms a stable complex with LKB1, MO25, 
and STRADβ, and does so in a manner that depends on HUNK kinase activity.  These 
data indicate that HUNK is a potential effector for LKB1-dependent phenotypes. 
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INTRODUCTION. 
LKB1 was first identified as the gene whose germline mutation and inactivation 
results in Peutz-Jeghers syndrome (PJS).  In addition to mucocutaneous pigmentation, 
nearly half of PJS patients present with small bowel obstruction at an early age due to the 
formation of benign gastrointestinal polyps that typically require repeated surgical 
interventions.23,24   
PJS patients also exhibit an elevated risk of cancers of the colon, rectum, breast, 
small bowel, gastrointestinal tract, and pancreas17,18, with the lifetime risk of cancer as 
much as 18 times higher than the general population.25  Consistent with LKB1’s 
identification as a bona fide tumor suppressor, somatic mutation or deletion of LKB1 
(STK11) occurs in 15-20% of lung adenocarcinomas and in 1-10% of cancers of the 
ovary, bladder, cervix, pancreas, esophagus, stomach, thyroid, colon and breast.32–39 
In recent years, the view of LKB1 as a classical tumor suppressor has been 
complicated by evidence demonstrating that LKB1 can support tumor cell survival and 
proliferation through a number of mechanisms.144  Contrary to its mutational inactivation 
in the germline of PJS patients, LKB1 is amplified in pancreatic cancers, sarcomas, 
adrenocortical carcinomas and gliomas145,146, forced expression of LKB1 promotes cell 
viability under energy stress, and LKB1 expression is associated with poor patient 
survival in hepatocellular carcinoma (HCC).56  These findings suggest that contexts may 
exist in which LKB1 activation promotes cancer. 
LKB1 regulates a range of cellular processes including metabolism, proliferation, 
apoptosis, and polarity, exerting these effects through activation of 14 of the 17 AMPK 
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related kinases (ARKs).9,10,56  Consistent with this, emerging evidence supports roles for 
ARKs in promoting cancer.  For example, AMPK is highly activated in as many as 40% 
of human prostate cancers and is required for cell proliferation and survival in multiple 
prostate cancer cell lines.73 AMPK promotes lung tumor cell survival during metabolic 
stress by maintaining NADPH homeostasis, allowing cells to buffer ROS (reactive 
oxygen species).69  NUAK1/ARK5 is required for the maintenance of metabolic 
homeostasis and prevention of apoptosis due to collapse of cellular ATP levels in a 
mouse model of MYC-driven hepatocellular carcinoma (HCC).147,148  NUAK2/SNARK 
is amplified in a range of cancers, is required for melanoma cell proliferation and mTOR 
activity, and its expression is associated with poor patient outcome in melanoma.149,150 
Of the 17 ARKs, HUNK (Hormonally Up-regulated Neu-associated Kinase) is the 
last to be experimentally evaluated as a substrate of LKB1.  HUNK was originally 
identified in a tumor from an MMTV-HER2/neu transgenic mouse11, suggesting a 
potential role in tumorigenesis, and several lines of evidence have implicated HUNK in 
the development and progression of cancers of the breast, ovary and colon.6–8  Given the 
association of LKB1, HUNK and other ARKs with carcinogenesis, as well as sequence 
homology among ARKs within the kinase T-loop phosphorylated by LKB1, we asked 
whether LKB1 could regulate HUNK kinase activity and, thereby, whether HUNK could 
be an effector of LKB1-dependent phenotypes. 
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EXPERIMENTAL PROCEDURES 
Immunoprecipitation kinase assays.  Cells were lysed in 50 mM Tris pH 7.4, 
150 mM NaCl, 10% glycerol, 1% Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 
HALT protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific).  Triton 
was diluted to 0.5% before combining lysates for each reaction of a given protein (batch 
IP) with magnetic anti-FLAG antibody conjugated beads (SIGMA-ALDRICH) for two 
hours at 4°C.  Beads were washed four times with modified lysis buffer containing 0.4% 
Triton X-100, washed three times in kinase reaction buffer without ATP, and then 
aliquoted into separate tubes.  Kinase reaction buffer was 50 mM HEPES pH 7.4, 25 mM 
NaCl, 100 μM EGTA, 14.2 μM BME, 5 mM Mg(OAc)2, 100 μM ATP, 1/100 HALT 
phosphatase inhibitor cocktail (Thermo Fisher Scientific), and 250 μCi/mL [γ-32P]-ATP.  
One reaction omitted radioactive ATP and was used for immunoblotting.  Reactions were 
incubated at 30°C for 30 min, then quenched with 0.5 M EDTA (final concentration 20 
mM) before mixing with 5X reducing sample buffer and boiling for 5 min at 95°C.  
FLAG antibody was from Abcam, GST, LKB1, and MO25 antibodies were from Cell 
Signaling, STRADα antibody was from Abnova, STRADβ antibody was from SIGMA.  
Densitometry of immunoblots and radiographs was performed using ImageStudio (LI-
COR Biosciences). 
Immunoblot analysis.  Membranes were probed with peroxidase-conjugated 
secondary antibodies (Jackson Laboratories) or Alexa-Fluor antibody (Molecular 
Probes).  Bound antibodies were detected with Luminata Classico Western HRP substrate 
(Millipore) or using the Odyssey detection system (LI-COR Biosciences).  The following 
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primary antibodies were used during Western blotting: HUNK 6; FLAG (Abcam); GST 
(Cell Signaling); LKB1 (Cell Signaling); MO25 (Cell Signaling); STRADα (Abnova); 
STRADβ (SIGMA); GAPDH (Cell Signaling). 
Proteins.  Purified recombinant LKB1/GST-MO25/GST-STRAD (SIGMA-
ALDRICH) was used at a final concentration of 66 ng/μL.  HUNK was generated by 
transient transfection of HEK-293T cells using Lipofectamine 2000 (Thermo Fisher 
Scientific) according to the manufacturer’s recommendation.  Mutant alleles of HUNK 
were generated (GeneArt Strings, Life Technologies), double digested, and ligated into 
the pBlueScript-KSII(+)-mHUNK before shuttling the modified HUNK gene into the 
pK1 retroviral vector 7.  TNT® Quick Coupled Transcription/Translation System 
(Promega) was used following the manufacturer’s instructions.   
Cell Culture.  Cells were grown at 37°C in 5% CO2.  HEK-293T and NAF 
(Nipple Aspirate Fluid) cells were maintained in DMEM (Mediatech) supplemented with 
10% FBS (Gibco), 200 nM glutamine (Gibco), and 1% penicillin/streptomycin (Gibco).  
NAF cells were infected with viral particles (SIGMA-ALDRICH) generated from the 
pLKO vector expressing shRNA against either LKB1 (TRCN0000024144, 
TRCN0000024145, TRCN0000024146) or non-targeting control (SHC002V).  After 
selection with 2 ug/mL puromycin, the pLKO infected NAF cells were then infected with 
pK1-FLAG-HA-mHUNK-WT viral particles. 
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RESULTS 
 
The T-Loop of HUNK exhibits moderate homology to other AMPK family kinases. 
LKB1 phosphorylates a conserved threonine within the T-loop of multiple ARKs 
to increase kinase activity (Figure 3A).  LKB1 also phosphorylates a conserved serine 
residue at +4 in MARKs 1, 2 and 3 9.  Members of the ARK family show strong 
conservation of amino acid residues surrounding the LKB1 phosphorylation site, with all 
fourteen previously identified LKB1 ARK substrates exhibiting perfect conservation at -
2, +2, +3, and +4 (Figure 3B).  
Inspection of the sequences of ARKs surrounding the conserved threonine 
phosphorylated by LKB1 fails to reveal any obvious basis for distinguishing the 14 
LKB1-regulated kinases from the two ARKs, NIM1 and MELK, not regulated by LKB1.  
However, the absence of LKB1 regulation of NIM1 and MELK appears to result from the 
ability of these kinases to autophosphorylate this conserved T-loop threonine 9,10.  The 
single remaining ARK for which LKB1 regulation had not previously been tested, 
HUNK, possesses each of the conserved T-loop residues at +2, +3 and +4, but is the only 
ARK lacking conservation of the leucine at -2, which is replaced by phenylalanine – 
another large hydrophobic residue.  In addition, HUNK is the only ARK with a glutamine 
residue at +1.  Based on this lower degree of sequence homology relative to other ARKs, 
it has been predicted that HUNK would not be a substrate for LKB1 10,62.  Nevertheless, 
alignment data remain compatible with the possibility that HUNK is an LKB1 substrate 9.    
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Figure 3.  The T-loop of HUNK has moderate homology with other AMPK family 
kinases.  (A) AMPK family tree of human kinases.  NIM1 and MELK are not regulated 
by LKB1 and are indicated in red.  (B) Alignment of T-loop residues of AMPK family 
members.  As NIM1 and MELK are not regulated by LKB1, they were omitted from 
generation of the consensus sequence.  The large * indicates the conserved threonine 
phosphorylated by LKB1 in each of the kinases listed in black.  The small * indicates the 
serine phosphorylated in MARKs 1-3 by LKB1.   
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LKB1 phosphorylates T222 of HUNK and stimulates HUNK kinase activity.   
To determine whether HUNK is regulated by LKB1 phosphorylation, we 
generated an alanine substitution mutant of HUNK lacking the T-loop threonine 
conserved within LKB1 substrates (T222A).  As negative controls, we compared the 
activity of WT HUNK and T222A HUNK both to a kinase-dead allele of HUNK in 
which lysine 91 within the HUNK ATP-binding domain is substituted with methionine 
(K91M), and to an empty vector control 6.   
Lysates from HEK-293T cells transiently transfected with the corresponding 
FLAG-HUNK vectors were batch immunoprecipitated using anti-FLAG antibodies 
conjugated to magnetic beads and kinase reactions were performed, with or without 
addition of purified recombinant LKB1/MO25/STRAD to the reaction.  Anti-FLAG 
beads from each immunoprecipitation reaction were evenly divided between eight kinase 
reactions.  Six reactions used [γ-32P]-ATP to generate autoradiographs, three with and 
three without recombinant LKB1.  Two reactions did not use [γ-32P]-ATP, one with and 
one without LKB1, and were used for immunoblotting.  The relative specific activity of 
HUNK phosphorylation in each reaction was calculated in the presence or absence of 
recombinant LKB1/MO25/STRAD.   
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Figure 4.  LKB1 phosphorylates T222 of HUNK to increase HUNK kinase activity.  
Immunoprecipitation kinase assay using [γ-32P]-ATP and anti-FLAG antibody-
conjugated magnetic beads.  FLAG-tagged HUNK mutants were expressed by transient 
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transfection of HEK-293T cells.  (A) Autoradiographs from immunoprecipitation kinase 
assays.  (B) Western blot for FLAG-tagged HUNK and GST-fusions of MO25 and 
STRAD in immunoprecipitation kinase reactions.  (C) Relative HUNK specific activity 
as measured by densitometry of HUNK in autoradiographs, normalized to HUNK 
expression from the anti-FLAG blot with wild type HUNK activity in the absence of 
recombinant LKB1 set to 100%.  Quantified levels are shown as means +/- standard 
deviation of three reactions performed in parallel.  Data are representative of two separate 
experiments. 
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Wild type HUNK showed greater signal in the autoradiographs than any other 
mutant (Figure 4).  WT also showed an altered distribution in both autoradiograph and 
immunoblot, displaying a basal band similar to that found in T222A and K91M, and 
showing signal in a region of lower electrophoretic mobility.  Addition of LKB1 to the 
WT reaction increased total phosphate on HUNK throughout the band in the 
autoradiograph, and LKB1 increased HUNK in the lower mobility region of the 
immunoblot, suggesting that LKB1 activates HUNK as it does the other ARKs.  As this 
region of lower mobility HUNK is increased in vitro by recombinant LKB1 and is only 
present in the WT reactions, it is most likely due to increased HUNK kinase 
autophosphorylation resulting in a hyperphosphorylated region of protein. 
Residual HUNK phosphorylation, above background in Empty vector lanes, was 
observed for the K91M and T222A mutants.  However, the lower mobility region of 
phosphate signal on HUNK was not observed for kinase reactions involving these alleles, 
irrespective of LKB1 addition, suggesting that these mutants have reduced kinase 
activity.  In the absence of LKB1 addition, the T222A allele displayed 2.6 times the 
phosphorylation of K91M HUNK, indicating greater basal activity for the T222A mutant.  
However, upon addition of LKB1, phosphorylation of K91M increased twelve-fold, 
whereas T222A phosphorylation increased only three-fold, resulting in twice as much 
phosphate deposited on K91M as on T222A (Figure 4).  This is consistent with a model 
in which the T222A mutation results in loss of the major site of LKB1 phosphorylation of 
HUNK, and a failure of LKB1-induced HUNK activation. 
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The increased phosphorylation of WT HUNK as compared to T222A, in the 
absence of recombinant LKB1, may reflect a difference in LKB1 activation of HUNK in 
the cells from which HUNK was immunoprecipitated, which would predict that the loss 
of LKB1 activity in these cells would lead to a loss of HUNK activity 
immunoprecipitated from those cells, a prediction we confirmed in subsequent 
experiments. 
 
LKB1 phosphorylation of HUNK outside the T-loop fails to increase kinase activity. 
In the previous experiment, we saw that while LKB1 could not induce production 
of a hyperphosphorylated band on the T222A mutant of HUNK, it could increase 
phosphorylation of the basal band, suggesting phosphorylations at residues other than the 
conserved threonine, possibly outside of the T-Loop.  To investigate the extent of LKB1 
phosphorylation of HUNK outside of the T-loop, we generated FLAG-tagged alanine 
substitution mutants of HUNK lacking one (S217), three (S217/S221/T222), or all five 
(S208/S217/S221/T222/S226)) of the serine and threonine residues within the T-Loop, 
hereafter referred to as mutants 1A, 3A, and 5A (Figure 5).  If the 5A mutant is 
phosphorylated by LKB1, those events must be occurring at residues outside of the T-
Loop.  We generated these mutants on either a WT or K91M (kinase dead) background, 
expressed each by transient transfection of HEK-293T cells, and performed 
immunoprecipitation kinase assays on lysates from each transfection . 
As predicted, all three K91M-based alleles of HUNK (K91M-1A, - 3A, -5A) 
exhibited lower levels of phosphorylation than the corresponding WT alleles of HUNK 
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(WT-1A, -3A, -5A) in the absence of LKB1, and none of the K91M alleles exhibited a 
hyperphosphorylated band in the presence of LKB1 (Figure 5).  In contrast to the K91M 
mutation, alanine substitution at S217 of HUNK (WT-1A) did not impair basal activity of 
HUNK, the extent of LKB1-induced phosphorylation, or the formation of a 
hyperphosphorylated band in response to LKB1 addition (Figure 5).  This suggests that 
the S217A mutation impairs neither basal, nor LKB1-stimulated, HUNK activity.  
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Figure 5.  LKB1 phosphorylation of HUNK outside the T-Loop fails to activate 
HUNK.  Immunoprecipitation kinase assays using [γ-32P]-ATP and anti-FLAG antibody-
conjugated magnetic beads.  FLAG-tagged HUNK mutants were expressed by transient 
transfection of HEK-293T cells.  (A) Western blot for FLAG-tagged HUNK and GST-
fusion MO25 and STRAD in immunoprecipitation kinase assays.  (B) Autoradiographs 
from immunoprecipitation kinase assays.  (C) Relative HUNK specific activity as 
measured by densitometry of HUNK in autoradiographs, normalized to HUNK 
expression from the anti-FLAG blot with wild type HUNK activity in the absence of 
recombinant LKB1 set to 100%.  Data are representative of two experiments, each 
performed without replicate reactions.  
P a g e  | 39 
 
 
Consistent with the presence of an alanine substitution at T222 in WT-3A and 
WT-5A, basal phosphorylation of these HUNK alleles was reduced in the absence of 
LKB1, and LKB1 addition induced only a two-fold increase in phosphate on these alleles 
(Figure 5), similar to that observed for the T222A single mutant (Figure 4).  In addition, 
neither the WT-3A nor WT-5A mutants exhibited a hyperphosphorylated band in the 
presence or absence of LKB1, consistent with an inability of LKB1 to activate alleles of 
HUNK lacking T222. 
As before, alleles of wild type HUNK bearing the T222A substitution (WT-3A, -
5A) showed a modest reduction in basal phosphorylation compared to WT and WT-1A 
alleles of HUNK in the absence of exogenously added recombinant LKB1 heterotrimer, 
that remained higher than those observed for K91M alleles of HUNK (Figure 5).  In 
contrast, alleles of K91M HUNK bearing the T222A substitution (K91M-3A, -5A) 
exhibited levels of basal phosphorylation that were similar to those of K91M alleles 
lacking the T222A substitution (K91M, K91M-1A).  This observation is consistent with 
the possibility that the higher residual levels of basal phosphorylation exhibited by WT 
HUNK alleles retaining T222 compared to HUNK K91M alleles is due to HUNK 
activation by endogenous LKB1. 
Notably, while basal HUNK phosphorylation was greater for the WT-3A and 
WT-5A alleles than for the K91M-3A and K91M-5A alleles, all achieved similar levels 
of phosphorylation upon addition of LKB1 (Figure 5).  Since the WT-5A and K91M-5A 
alleles do not contain serine or threonine residues within their respective T-loops, this 
implies that the LKB1-induced increase in phosphorylation observed for these alleles 
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reflects an increase in phosphate deposited during the kinase reaction by LKB1 outside of 
the T-loop of HUNK.  However, since none of these alleles exhibits a 
hyperphosphorylated band in the presence of LKB1, or an overall level of 
phosphorylation exceeding that of WT HUNK in the absence of LKB1, these findings 
suggest that LKB1 phosphorylation outside of the T-loop of HUNK has little effect on 
kinase activity. 
 
LKB1 activates HUNK in a reconstituted system in vitro. 
To extend our findings regarding LKB1 activation of HUNK, in vitro translated 
HUNK-WT, HUNK-K91M, or empty vector control was used as input for 
immunoprecipitation kinase assays with and without addition of recombinant LKB1 
heterotrimer (Figure 6).  Consistent with our prior results, in the absence of LKB1 a 
hyperphosphorylated form of HUNK was evident for HUNK-WT, but not HUNK-K91M, 
indicating that wild type HUNK has intrinsic basal activity (Figure 6).  In the presence of 
LKB1, both WT and K91M HUNK exhibited a basal phosphorylated band of equivalent 
intensity, whereas only WT HUNK exhibited a hyperphosphorylated band, and this band 
was markedly enhanced by LKB1 addition.  This indicates that LKB1 can activate WT 
HUNK in vitro in the absence of factors that might otherwise co-immunoprecipitate with 
HUNK from cell lysates.  
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Figure 6.  LKB1 activates in vitro translated HUNK.  Immunoprecipitation kinase 
assay using [γ-32P]-ATP and anti-FLAG antibody-conjugated magnetic beads.  FLAG-
HUNK mutants were expressed using TNT® Quick Coupled Transcription/Translation 
System.  (A) Autoradiograph from immunoprecipitation kinase assays.  (B) Western blot 
for FLAG-HUNK and GST-MO25 and GST-STRAD in immunoprecipitation kinase 
assays.  (C) Relative HUNK specific activity as measured by densitometry of HUNK in 
autoradiographs, normalized to HUNK expression from the anti-FLAG blot with wild 
type HUNK activity in the absence of recombinant LKB1 set to 100%.  Single 
experiment.  
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LKB1 controls HUNK activation in vivo. 
We next asked whether LKB1 activity is a physiologically significant determinant 
of HUNK activity in cells.  As activation of LKB1 requires complex formation 50, we 
hypothesized that up-regulating expression of the LKB1/MO25/STRAD heterotrimer 
would be sufficient to increase LKB1 activity in cells and would, in turn, result in 
increased activation of HUNK.  Conversely, we hypothesized that down-regulating 
LKB1 activity in cells by expressing the dominant negative, kinase-inactive mutant of 
LKB1, D194A 61, would result in decreased activation of HUNK. 
To test this hypothesis, HEK-293T cells were simultaneously transfected with 
expression vectors for HUNK, LKB1 (WT or D194A), MO25 and STRAD.  Control cells 
were transfected with a vector encoding HUNK, but not vectors encoding the LKB1 
heterotrimer.  Kinase assays were performed using HUNK immunoprecipitated from 
each of these cell lysates. 
As before, a hyperphosphorylated band was observed for WT HUNK 
immunoprecipitated from HEK-293T cells in the absence of expression of exogenous 
LKB1 (Figure 7).  Consistent with our prior kinase assays using recombinant 
LKB1/MO25/STRAD, cells transfected with vectors encoding HUNK and wild type 
LKB1/MO25/STRAD exhibited a four-fold increase in HUNK phosphorylation, 
predominantly within the hyperphosphorylated band.  In contrast, HUNK from cells 
transfected with dominant negative LKB1-D194A showed a four-fold reduction in the 
hyperphosphorylated form of HUNK (Figure 7).  These data provide additional evidence 
supporting the phosphorylation and activation of HUNK by LKB1, and further suggest 
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that basal HUNK activity (i.e., HUNK activity in the absence of exogenously added 
LKB1) in mammalian cells may reflect activation by endogenous LKB1. 
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Figure 7.  LKB1 controls HUNK activation in vivo.  Immunoprecipitation kinase assay 
using [γ-32P]-ATP and anti-FLAG antibody-conjugated magnetic beads.  FLAG-HUNK, 
HA-LKB1, HA-MO25, and HA-STRAD were simultaneously transfected into HEK-
293T cells.  (A) Autoradiographs from immunoprecipitation kinase assays.  (B) 
Immunoblot for FLAG-HUNK in immunoprecipitation kinase reactions.  (C) 
Immunoblot for LKB1 in lysates from which HUNK was immunoprecipitated.  (D) 
Relative HUNK specific activity as measured by densitometry of HUNK in 
autoradiographs, normalized to HUNK expression from the anti-FLAG blot with wild 
type HUNK activity in the absence of recombinant LKB1 set to 100%.  Single 
experiment.  
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Endogenous LKB1 is required for HUNK activation in cells. 
We next asked whether endogenous LKB1 is required for HUNK kinase activity 
in cells.  We stably expressed shRNAs against LKB1 or a scrambled control hairpin in 
NAF cells, a mouse MMTV-neu cell line known to have a high level of basal HUNK 
activity 7. 
Consistent with our observations following transfection of a dominant-negative, kinase-
dead allele of LKB1, HUNK from lysates from cells in which LKB1 was knocked down 
exhibited a reduction in HUNK activity, compared to control shSCR cells (Figure 8).  
This further supports the hypothesis that endogenous LKB1 is required for HUNK 
activation in cells.   
 
WT HUNK Binds LKB1, MO25, and STRADβ but not STRADα. 
Given our identification of HUNK as a substrate for the LKB1 complex, we 
sought to determine whether HUNK forms a stable complex with the LKB1 heterotrimer 
by co-immunoprecipitation assays from mammalian cells.  FLAG-tagged HUNK was 
expressed by transient transfection in 293T cells, then immunoprecipitated using anti-
FLAG antibody conjugated magnetic beads.  This revealed that WT HUNK stably bound 
to LKB1, MO25, and STRADβ but not to STRADα (Figure 9).  
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Figure 8.  LKB1 is required for HUNK kinase activity in vivo.  Immunoprecipitation 
kinase assay using [γ-32P]-ATP and anti-FLAG antibody conjugated magnetic beads.  
Endogenous HUNK was immunoprecipitated from NAF cells which were infected with 
vectors expressing shRNA against LKB1 or a scrambled control hairpin.  (A) 
Autoradiograph from immunoprecipitation kinase assay.  (B) Immunoblots for HUNK in 
an immunoprecipitation kinase assay and for LKB1 in crude lysates from which HUNK 
was immunoprecipitated.  (C) Relative specific activity as measured by densitometry of 
HUNK in both blot and autoradiograph.  Single experiment.  
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Figure 9.  WT HUNK binds LKB1, MO25, and STRADβ but not STRADα.  Co-
immunoprecipitation assay using anti-FLAG antibody conjugated magnetic beads.  
FLAG-HUNK mutants were expressed by transient transfection of HEK-293T cells.  
Single experiment.   
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DISCUSSION  
We have shown for the first time that LKB1 phosphorylates and regulates the 
AMPK-related kinase, HUNK.  Specifically, our in vitro and in vivo data indicate that 
LKB1 phosphorylates HUNK at a conserved threonine (T222), resulting in substantial 
increases in HUNK kinase activity.  In addition, experiments using in vitro translated 
HUNK suggested that LKB1 phosphorylation of HUNK requires only the components of 
the LKB1 heterotrimer.  Further data indicated that while LKB1 can phosphorylate 
HUNK in vitro at residues outside the T-loop, these sites do not appear to contribute to 
the LKB1-mediated regulation of HUNK activity.  HUNK exhibited some basal activity 
in the absence of exogenously added LKB1, including in vitro translation experiments, 
however this may be attributable – at least in part – to endogenous LKB1 activity, since 
transfection of dominant-negative LKB1 into cells resulted in decreased HUNK kinase 
activity.  Finally, our results reveal that LKB1 is required for HUNK activity in vivo as 
knockdown of endogenous HUNK significantly reduces HUNK kinase activity.  
It has been previously been proposed that a leucine at -2 might be required for 
LKB1 phosphorylation of ARK substrates10,62.  However, since HUNK has a 
phenylalanine residue at -2, this may indicate that other large, hydrophobic residues at 
this position may suffice.  In this regard, it has been reported that LKB1 phosphorylates 
p53, PAK1, and PTEN at peptide sequences that share little homology with ARK T-loop 
sites133–135.  This suggests that LKB1 substrate selection may be less restricted than 
originally suspected.  As such, it is possible that other substrates of LKB1 exist that also 
lack the leucine at -2, although it is known that several kinases (TSSK1-4, SSTK) that 
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lack all conserved T-Loop residues N-terminal to the conserved threonine are not 
regulated by LKB110. 
Multiple lines of evidence implicate HUNK in promoting the development and 
progression of cancers in a variety of contexts.  For example, HUNK expression is 
significantly higher in aggressive subsets of human cancer, including lymph node 
positive breast cancers, HER2/neu-expressing breast cancers, and poorly differentiated 
cancers of the breast, ovary, and colon6.  Consistent with a functional role for HUNK in 
tumorigenesis, HUNK is required for primary mammary tumor formation in mouse 
models of breast cancer driven by HER2/neu overexpression or PTEN deletion7,8, and 
HUNK is required for the metastasis of mammary tumors driven by c-MYC6.   
The realization that LKB1 activates HUNK raises the possibility that HUNK may 
serve as an effector for LKB1-dependent tumor suppressive phenotypes.  In this regard, 
some reports have implicated HUNK in the negative regulation of proliferation of 
intestinal epithelial cells and in the suppression of metastasis of basal-subtype breast 
cancer cells151,152.  However, in light of demonstrated roles for HUNK in promoting the 
development and progression of cancers in a variety of contexts6–8, a perhaps more 
interesting possibility is that HUNK may serve as an effector for LKB1-dependent 
phenotypes that promote cancer cell survival and tumor progression, for which recent 
evidence has emerged56,144,153. 
In this regard, there are several LKB1-dependent phenotypes for which the 
effectors responsible have yet to be elucidated.  For example, recent work has uncovered 
links between LKB1 and the DNA damage response (DDR), whereby LKB1 controls 
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BRM-dependent non-homologous end joining, and cells deficient for LKB1 exhibit 
marked increases in chromosomal aberrations140.  In an analogous manner, LKB1 
haploinsufficient mice show dramatically increased sensitivity to UVB-induced skin 
cancer, and both these mice and LKB1-deficient human keratinocytes exhibit impaired 
repair of UVB-induced DNA damage141.  LKB1 reduces mutation rate and increases 
survival after DNA damage by stimulating BRCA1 expression in an at least partially 
AMPK-dependent manner138.  Whether HUNK may play a role in mediating effects of 
LKB1 on DNA damage responses remains to be determined. 
Furthermore, there are mechanistically unexplained links between LKB1 and 
TGF-β signaling.  TGF-β, like LKB1, has been reported to function as a tumor suppressor 
during early stages of tumorigenesis, but as a tumor promoter in later stages of 
tumorigenesis154,155.  The gastrointestinal tracts of mice deficient for stromal LKB1 form 
polyps indistinguishable from PJS polyps156.  While LKB1-/- stromal cells exhibit 
unperturbed mTOR, AMPK, SRF, RhoA, and FAK signaling157, they produce less TGF-
β, a defect which results in increased proliferation of epithelial cells in both murine and 
human PJS tissues158.  As both HUNK and TGF-β have been shown to down-regulate 
MYC expression8, it is intriguing to speculate that HUNK may play a role in mediating 
the relationship between LKB1 and TGF-β signaling. 
Our findings that wild type HUNK binds to the LKB1 heterotrimer far more 
efficiently than does HUNK-K91M, and that wild type HUNK binds heterotrimeric 
complexes with STRADβ, but not STRADα, raises at least three questions.  First, why 
does HUNK-WT bind STRADβ but not STRADα?  Much of the literature on LKB1 does 
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not differentiate between STRAD isoforms, which may neglect important aspects of 
regulation of LKB1 signaling.  STRADα is known to promote the activation and nuclear 
export of LKB1/MO25, whereas STRADβ can activate LKB1 but does not appear to 
affect its subcellular localization, potentially allowing activated LKB1 to remain in the 
nucleus51.  As HUNK-WT, STRADα, and STRADβ can each be found in the nucleus as 
well as in the cytoplasm51,159, the differential binding of HUNK to  STRADα and 
STRADβ may be due either to structural differences between the STRAD isoforms that 
influence HUNK binding, or to scaffolds or chaperones found only in the nucleus. 
Second, why does HUNK-K91M fail to bind the LKB1 heterotrimer?  One 
possible explanation is that binding occurs in the nucleus, from which HUNK-K91M is 
excluded159.  Another possibility is that STRADβ binding to HUNK may occur at sites 
created by HUNK autophosphorylation.  To our knowledge, our data are the first to 
suggest that kinase activity of an LKB1 substrate may alter binding to LKB1.  
Third, does HUNK binding to the nuclear specific complex of 
LKB1/MO25/STRADβ affect its nuclear/cytoplasmic distribution?  Such binding has 
been seen to alter distribution in the case of the orphan nuclear receptor Nur77, with the a 
resulting reduction in AMPK activation60.  It is possible that HUNK stabilizes LKB1 in a 
complex that is localized to the nucleus, thus altering compartment specific activity of the 
LKB1 heterotrimer. 
In conclusion, we show that HUNK is phosphorylated and activated by LKB1 in 
vivo and in vitro, and thereby identify HUNK as a potential mediator of LKB1-dependent 
effects.  This possibility is consistent with the emerging appreciation of tumor promoting 
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effects of LKB1, and the demonstration that HUNK can promote tumorigenesis and 
tumor cell survival in multiple biological contexts.  Our data additionally suggest the 
value of further investigation into the potential roles of HUNK as an LKB1 effector in the 
contexts of tumor suppression, control of TGF-β signaling, and regulation of DNA 
damage repair, and raise the possibility that different isoforms of STRAD may have 
differential impacts on LKB1-mediated signal transduction. 
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CHAPTER 3: IDENTIFICATION OF CHK2 AND CAMKKβ AS 
SUBSTRATES OF HUNK 
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ABSTRACT. 
To identify substrates of HUNK kinase, we performed kinase assays on protein 
microarrays and compared results for arrays treated with WT or K91M (kinase dead) 
HUNK to generate a ranked list of candidate substrates.  To date, we have used 
immunoprecipitation kinase assays to confirm two substrates, CAMKKβ and CHK2.  
CAMKKβ and HUNK phosphorylate each other, and this interaction does not alter kinase 
activity of CAMKKβ.  We also showed that HUNK is required for efficient activation of 
the ATM/CHK2 pathway in response to DNA damage in cells. 
 
INTRODUCTION. 
There are over 500 human kinases representing about 1.7% of all human genes 
and, together, these enzymes mediate much of the signal transduction in eukaryotic cells2.  
Further, by altering the activity of catalytic enzymes, kinases control diverse cellular 
processes, and mutation of kinases underlies many human diseases160.  The primary mode 
of control is phosphorylation of substrates, thus knowledge of which substrates a kinase 
phosphorylates provides insight into its function.   
There are many methods for identification of kinase substrates.  Chemical 
genetics, also known variously as the bump kinase, Shokat kinase, or analog specific 
approach, requires mutating the active site of the kinase so it can accept an analog of 
ATP modified with a bulky alkyl moiety that makes unaltered kinases unable to catalyze 
phosphotransfer161.  This approach has several elegant variations, but all depend on being 
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able to mutate the kinase of interest while retaining kinase activity.  HUNK did not meet 
this requirement (data not shown), so other approaches were sought. 
Phage display allows the screening of many proteins or peptides at once through 
phosphorylation of material displayed on the surface of transfected bacteria162.  Several 
variations of screens based on identifying candidate substrates through their binding to 
the kinase of interest exist, but the binding between kinase and substrate is often 
transient, and these methods are prone to false positives as they identify binding partners 
and complex members as candidate substrates163. 
There are a multitude of approaches using mass spectrometry, including stable 
isotope labeling by amino acids in cell culture (SILAC), in which experimental cells are 
grown in media lacking an essential amino acid but supplemented with a non-radioactive, 
isotopically labeled form of that amino acid164.  Experimental cells must also have altered 
activity in the kinase of interest, which can be achieved through various means including 
overexpression, knockout, knockdown, or chemical inhibition.  Lysates from 
experimental cells are combined with lysates from control cells grown in standard media 
and the mass shift between their resulting mass spectra identify candidate substrates. 
Another approach involves performing a kinase assay on a chip coated with either 
peptides or proteins.  This requires that the kinase of interest first be purified, ideally 
along with a kinase dead control.  This is the approach we took to identify substrates of 
HUNK kinase.  We performed kinase assays on protein microarrays and compared the 
results when the arrays were treated with WT or K91M (kinase dead) HUNK to generate 
a ranked list of candidate substrates. 
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Genetic evidence from HUNK-deficient mice has shown multiple roles for 
HUNK in the development and progression of cancers of the breast, ovary and colon6–8, 
in part by negatively regulating apoptosis.  HUNK is also linked to Akt and PTEN 
dependent effects, in particular control of apoptosis in the involuting mammary gland, in 
which forced overexpression of Akt rescues excessive apoptosis induced by HUNK 
deletion8.   These data provide hints as to possible effectors of HUNK kinase, framing 
our search for HUNK substrates. 
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EXPERIMENTAL PROCEDURES 
 
Buffers: 
M2 Lysis Buffer (M2LB): 50 mM Tris pH 7.4, 150 mM NaCl, 10% glycerol, 1% 
Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 HALT inhibitor cocktail (Thermo 
Fisher Scientific).   
M2 High Salt Wash (M2HSW): 50 mM Tris pH 7.4, 500 mM NaCl, 0.4% Triton 
X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 HALT inhibitor cocktail (Thermo Fisher 
Scientific). 
M2 Binding Buffer (M2BB): 50 mM Tris pH 7.4, 150 mM NaCl, 0.4% Triton X-
100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 HALT inhibitor cocktail (Thermo Fisher 
Scientific). 
M2 Dilution Buffer (M2DB): 50 mM Tris pH 7.4, 150 mM NaCl, 0.0% Triton X-
100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 HALT inhibitor cocktail (Thermo Fisher 
Scientific). 
HUNK Kinase Buffer (HKB): 25 mM HEPES pH 7.4, 0.1% TX-100, 1 mM DTT, 
0X HALT, 25 mM NaCl, 2.5 mM Mg(OAc)2. 
Tandem Affinity Tag Purification.  Cells were lysed in 50 mM Tris pH 7.4, 150 
mM NaCl, 10% glycerol, 1% Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 
HALT protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific), then snap 
frozen on dry ice/ethanol for later processing.   
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Lysates were thawed while inverting tubes to mix, then Triton X-100 was diluted 
to 0.5%.  Diluted lysates were incubated with anti-FLAG antibody conjugated beads for 
two hours at 4°C while being rotated.  Beads were then washed three times with M2BB, 
then eluted three times with 150 ng/uL 3XFLAG peptide (SIGMA-ALDRICH) in M2BB.  
Eluates were then incubated with anti-HA antibody conjugated beads for two hours at 
4°C while being rotated.  Beads were then washed three times with M2BB, then eluted 
three times with 1000 ng/uL HA peptide (SIGMA-ALDRICH) in M2HSW.  Eluted 
protein was frozen for later use on dry ice/ethanol. 
Before use in kinase assays, protein was thawed while inverting tubes to mix, then 
placed in 500 uL 10 kD MW cut off centrifugal concentrator (Millipore).  Three times the 
protein was concentrated to ~20 uL then diluted with HKB.  IP kinase assays were used 
to assess the activity of the protein using anti-HA antibody conjugated beads, 100 uM 
ATPγS, and the immunofluorescent approach described in the kinase assay on protein 
microarrays. 
Protein microarray kinase assays with ATPγS and immunofluorescence.  
ProtoArrays V5 (Thermo Fisher Scientific) were warmed from -20°C to 4°C for one 
hour, then blocked for one hour with 0.22 um filtered 1X PBS pH 7.4 (Thermo Fisher 
Scientific) with 1% protease-free BSA (SIGMA-ALDRICH).  120 uL reaction mixture 
derived from 2 ug purified and buffer exchanged HUNK in HKB with 100 uM ATPγS 
was added to each microarray, then the array was gently covered with a 50 mm coverslip 
and incubated at 30°C for 2 hours.  Arrays were washed twice for 15 minutes with 0.5% 
SDS, then three times for 3 minutes in 1X PBS-T (0.05% Tween-20).  Added 120 uL 2.5 
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mM PNBM (p-nitrobenzylmeslyate) in 1X PBS, coverslipped, and incubated 2.5 hours at 
room temperature. 
Arrays were washed 3 times for 3 minutes in 1X PBS-T.  120 uL anti-
thiophosphate ester (Abcam) in PBS-T and coverslip were added to arrays and they were 
incubated overnight at 4°C.  Slides were washed 4 times in PBS-T and then 120 uL goat-
anti-rabbit-Cy3 (Invitrogen) and coverslip were added and arrays were incubated for 2 
hours at room temperature.  Arrays were washed 5 times in PBS-T, rinsed three times in 
water, and spun dry in slide holders at 1000 RPM.  Arrays were imaged on a GenePix 
4000.  Quantifications were exported to excel and a linear regression line calculated 
giving predicted values on the HUNK-WT treated array as a function of values from the 
HUNK-K91M treated array. 
Immunoprecipitation kinase assays.  Cells were lysed 50 mM Tris pH 7.4, 150 
mM NaCl, 10% glycerol, 1% Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1/100 
HALT protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific).  Triton 
was diluted to 0.5% before combining lysates for each reaction of a given protein (batch 
IP) with magnetic anti-FLAG antibody conjugated beads (SIGMA-ALDRICH) for two 
hours at 4°C.  Beads were washed four times with modified lysis buffer containing 0.4% 
Triton X-100, washed three times in kinase reaction buffer without ATP, and then 
aliquoted into separate tubes.  Kinase reaction buffer was 50 mM HEPES pH 7.4, 25 mM 
NaCl, 100 μM EGTA, 14.2 μM BME, 5 mM Mg(OAc)2, 100 μM ATP, 1/100 HALT 
phosphatase inhibitor cocktail (Thermo Fisher Scientific), and 250 μCi/mL [γ-32P]-ATP.  
One reaction omitted radioactive ATP and was used for immunoblotting.  Reactions were 
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incubated at 30°C for 30 min, then quenched with 0.5 M EDTA (final concentration 20 
mM) before mixing with 5X reducing sample buffer and boiling for 5 min at 95°C.  
FLAG antibody was from Abcam, GST, LKB1, and MO25 antibodies were from Cell 
Signaling, STRADα antibody was from Abnova, STRADβ antibody was from SIGMA.  
Densitometry of immunoblots and radiographs was performed using ImageStudio (LI-
COR Biosciences).  [γ-18O4]-ATP (Cambridge Isotope Laboratories, >94% 18O on γ-
phosphate) was used at 100 uM and was the only ATP source used in kinase assays 
analyzed by mass spectrometry. 
Immunoblot analysis.  Membranes were probed with peroxidase-conjugated 
secondary antibodies (Jackson Laboratories) or Alexa-Fluor antibody (Molecular 
Probes).  Bound antibodies were detected with Luminata Classico Western HRP substrate 
(Millipore) or using the Odyssey detection system (LI-COR Biosciences).  The following 
primary antibodies were used during Western blotting: HUNK 6; FLAG (Abcam); GST 
(Cell Signaling); LKB1 (Cell Signaling); MO25 (Cell Signaling); STRADα (Abnova); 
STRADβ (SIGMA); GAPDH (Cell Signaling). 
Proteins.  HUNK was generated by stable infection of NAF cells with pK1-
FLAG-HA-mHUNK-WT, pK1-FLAG-HA-mHUNK-K91M, or pK1-Empty viral 
particles.  CAMKKβ-K194A and CHK2-K249R kinase dead proteins were generated by 
transient transfection of 293T cells with pK1-FLAG-HA expression vectors. 
Cell Culture.  Cells were grown at 37°C in 5% CO2.  HEK-293T and NAF cells 
were maintained in DMEM (Mediatech) supplemented with 10% FBS (Gibco), 200 nM 
glutamine (Gibco), and 1% penicillin/streptomycin (Gibco).  NAF cells were infected 
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with viral particles (SIGMA-ALDRICH) generated from the pLKO vector expressing 
shRNA against either LKB1 (TRCN0000024144, TRCN0000024145, 
TRCN0000024146) or non-targeting control (SHC002V).  After selection with 2 ug/mL 
puromycin, the pLKO infected NAF cells were then infected with pK1-FLAG-HA-
mHUNK-WT viral particles. 
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RESULTS 
 
Tandem Affinity Tag Purification of HUNK from NAF Cells. 
NAF cells are derived from a tumor in an MMTV-HER2/neu mouse and have 
been demonstrated to express high levels of HUNK protein12.  These cells were infected 
with retroviral particles to constitutively express FLAG-HA-mHUNK-WT and FLAG-
HA-mHUNK-K91M, as well as empty vector.  HUNK-K91M was used throughout as a 
control for co-immunoprecipitating kinase activity.   
The scheme used for purification and evaluation of HUNK is shown below 
(Figure 10).  Purification used two different affinity tags, FLAG and HA, and kinase 
activity and protein purity were evaluated before and after the purification. 
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Figure 10.  Scheme for Tandem Affinity Tag Purification of FLAG-HA-mHUNK 
from NAF Cell Lysate.  Briefly, cells were lysed using Triton X-100, lysates were 
bound to and eluted from antibody conjugated beads, and the activity and purity of the 
resulting protein was evaluated via silver stain and IP kinase assay. 
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Purification resulted in very high loss of starting material but yielded protein of 
high apparent purity when inspected on a silver stained gel (Figure 11).  The final yield 
was about 4% with the dominant band running at the same electrophoretic mobility as the 
HA-tag on HUNK shown in the immunoblot. 
The activity of the protein was assessed via immunoprecipitation kinase assay 
(IPKA) on anti-HA antibody conjugated beads, using ATPγS and immunofluorescence 
(Figure 12).  This approach was developed in the lab of Kevan Shokat and it uses ATPγS 
to thiophosphorylate kinase substrates in kinase reactions165.  After the kinase reaction, 
thiols present are alkylated using the agent PNBM (p-nitrobenzylmesylate), and then the 
thiophosphate ester is detected using a rabbit monoclonal antibody.  While not all 
enzymes are capable of catalyzing thiophosphorylation of substrate165, many, including 
HUNK, are. 
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Figure 11.  Silver Stain and Anti-HA-tag Western Blot from Tandem Affinity Tag 
Purification of FLAG-HA-mHUNK from NAF Cell Lysate.  Silver stain showing 
purity of protein at each stage.  HA-tag immunoblot showing relative HUNK protein at 
each stage of purification. 
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Figure 12.  Schematic for Kinase Assay using ATPγS and Immunofluorescence.  
Substrates are thiophosphorylated using ATPγS, then alkylated using PNBM.  The 
resulting thiophosphate ester is detected using a rabbit monoclonal antibody. 
 
The thiophosphate IPKA was used to compare the activity of the HUNK in the 
crude lysates to that present in the purified protein (Figure 13).   The ratio of 
thiophosphate to HA-tag was calculated as a measure of relative activity of the kinase in 
the IP.  This ratio dropped roughly forty-fold during the purification, indicating much of 
the activity of the kinase was lost during purification.  The ratio of WT to K91M relative 
activity decreased from 5 to 2, indicating that the final purified HUNK was yielding 
thiophosphate signal only twice as strong as the negative control K91M.  It is worth 
noting that the due to the workflow used, protein input amounts were not normalized and 
the amount of protein input was less for the post-purification samples.  This may have 
lowered the apparent activity of the purified protein, as we know that signal in the IPKA 
correlates with amount of protein on the beads (data not shown).  This protein from this 
purification was used for kinase assays on the protein microarrays.  
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Figure 13.  Immunoprecipitation kinase assay to evaluate activity of HUNK kinase 
before and after purification.  Briefly, NAF lysates or purified HUNK were 
immunoprecipitated, washed, and subjected to a kinase assay using ATPγS and 
immunofluorescence.  Single experiment. 
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Immunoprecipitation Kinase Assay on Protein Microarrays Using ATPγS and 
Immunofluorescence. 
ProtoArrays (V5, Thermo Fisher Scientific) were used to search for substrates of 
HUNK.  ProtoArrays are protein microarrays containing roughly 9,000 unique proteins.  
Proteins are expressed in insect cells as GST fusions and are placed in adjacent duplicate 
spots on a coated glass slide.  The spots are arranged in 48 blocks, each with recurring 
controls including autophosphorylating kinases and fluorescent spots. 
We performed kinase assays on ProtoArrays, treating one chip each with HUNK-
WT and HUNK-K91M.  The chips were imaged on a GenePix 4000 (Figure 14), the 
values were exported to excel and plotted spot vs. spot (Figure 15).  A linear regression 
line was calculated as Predicted_WT_Value = m * K91M_Value + b.  If the actual value 
for WT was greater than or equal to 4 * Predicted_WT_Value, and the two values for WT 
were similar, the protein in question was deemed a candidate substrate for HUNK (Table 
2).  If the actual value for WT was less than or equal to 0.25 * Predicted_WT_Value, the 
protein in question was highlighted on the chart (Figure 15). 
20 candidates were identified (two were CAMKKβ), including 8 kinases and 3 
MAPK pathway members.  22 proteins and 4 paired control spots had values for WT that 
were less than or equal to 0.25 * Predicted_WT_Value, indicating that our signal to noise 
ratio in this assay was poor.  Visual inspection of the immunofluorescence signals from 
imaging the protoarrays (Figure 14) shows high variability of the recurring control spots, 
with weak signals especially in the upper left and lower right sections of the arrays 
indicating possible uneven coverage of the array with the reaction mixture. 
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Figure 14.  Raw immunofluorescent images of ProtoArrays treated with HUNK.  
Each circle is a protein spotted on the ProtoArray and imaged via immunofluorescent 
detection of thiophosphate ester.  Single experiment.  
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Figure 15.  Chart showing spot vs. spot signal for ProtoArrays treated with either 
WT or K91M HUNK.  Candidate substrates were defined as having WT signal four 
times or more greater than that predicted from the K91M values.  26 paired spots had WT 
signal four times or more less than that predicted from the K91M values.  Note that 
CAMKK2/CAMKKβ and CHEK2/CHK2 are alternate names for the same two proteins. 
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Gene     
Symbol
Description
Avg WT 
Signal
Avg K91M 
Signal
WT Signal 
Predicted 
from K91M 
Signal
Actual WT 
Signal / 
Predicted WT 
Signal
CAMKK2 Calcium/calmodulin-dependent protein kinase kinase 2 2242 2 10 225
BAZ2B bromodomain adjacent to zinc finger domain, 2B 3884 87 81 48
PHF23 PHD finger protein 23 1468 177 156 9
SRPK3 SFRS protein kinase 3 2224 279 242 9
CHEK2 CHK2 checkpoint homolog (S. pombe) 2052 265 230 9
PRPF38A PRP38 pre-mRNA processing factor 38 (yeast) domain containing A 314 37 40 8
SMN2 survival of motor neuron 2, centromeric 335 42 44 8
NKAP NF-kappa-B-activating protein 120 9 16 7
HIRIP3 HIRA interacting protein 3 1237 232 203 6
C19orf43 chromosome 19 open reading frame 43 239 38 41 6
MAP3K13 mitogen-activated protein kinase kinase kinase 13 56 1 10 6
ASAP2 Development and differentiation-enhancing factor 2 98 12 19 5
SSRP1 structure specific recognition protein 1 480 104 95 5
PRKCA protein kinase C, alpha 1436 345 297 5
RTF1 Rtf1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) 231 47 48 5
POLB polymerase (DNA directed), beta 161 30 34 5
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 1820 501 428 4
MAPKAPK5 mitogen-activated protein kinase-activated protein kinase 5 191 44 45 4
PLK1 polo-like kinase 1 (Drosophila) 689 189 166 4
Table 3.  Ranked list of candidate substrates of HUNK.  Confirmed substrates 
highlighted in gray. 
 
HUNK phosphorylates CHK2 and CAMKKβ and this activity is increased by 
LKB1.   
Two candidates were tested for substrate verification.  CAMKKβ was chosen 
because it was the strongest candidate and CHK2 was chosen because work performed in 
our lab by Jason Jung indicated a role for HUNK in the DNA damage response.  In both 
cases, plasmids encoding FLAG-tagged, kinase dead variants were generated so as to 
avoid signal from autophosphorylation.  Proteins were expressed by transient transfection 
in HEK-293T cells.  CHK2-K249R protein lysate was found to inhibit HUNK activity 
(data not shown), so the protein was subjected to a rapid purification and buffer exchange 
over anti-FLAG antibody conjugated magnetic beads (SIGMA-ALDRICH) and 
centrifugal concentrator (Millipore). 
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Proteins were batch immunoprecipitated such that a portion of the beads could be 
used to assess protein loading via a non-radioactive IP kinase assay and part used for 
radioactive IP kinase assays with and without the addition of purified recombinant 
LKB1/MO25α/STRADα (SIGMA-ALDRICH). 
Incubation with WT but not K91M HUNK resulted in a significant increase in 
phosphate deposited upon CHK2 and CAMKKβ, indicating that HUNK phosphorylates 
these proteins in vitro (Figure 15).  The phosphate deposited on HUNK, CHK2, and 
CAMKKβ each increased when LKB1 heterotrimer was added to reactions with WT 
HUNK, indicating that the increase in HUNK activity induced by LKB1 as measured by 
autophosphorylation (Chapter 2) also results in increased phosphorylation of HUNK 
substrates. 
HUNK-WT basal activity was reduced by co-IP with CHK2-K249R as compared 
to co-IP with CAMKKβ-K194A, which may indicate that CHK2-K249R associates with 
HUNK in a manner that either impairs kinase activity or reduces access to HUNK 
autophosphorylation sites.  The increase in substrate phosphorylation induced by LKB1 
was greater for HUNK phosphorylation of CHK2-K249R than for CAMKKβ-K194A, 
though that may be due HUNK phosphorylation of CAMKKβ-K194A being nearly 
saturated in this experiment while HUNK phosphorylation of CHK2-K249R was not. 
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Figure 16.  HUNK phosphorylates CHK2 and CAMKKβ and this activity is 
increased by LKB1.  Immunoprecipitation kinase assay using [γ-32P]-ATP and anti-
FLAG antibody-conjugated magnetic beads.  Proteins were expressed by transient 
transfection of HEK-293T cells.  (A) Immunoblots from batch IP showing protein 
loading on IP kinase assay.  (B) Three autoradiographs taken at different exposures to the 
gels from the IP kinase assay.  (C) Quantification of phosphate deposited on CHK2-
K249R or CAMKKβ-K194A.  Data are representative of more than three experiments, 
each performed without replicate reactions. 
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HUNK is required for efficient activation of ATM and CHK2 in response to DNA 
damage. 
To test whether HUNK phosphorylation of CHK2 may be physiologically 
significant, we evaluated activation of the ATM/CHK2 pathway in cells after DNA 
damage.  LS174T human colon carcinoma cells were stably infected with hairpins against 
either GFP as a negative control or against HUNK.  NAF mouse MMTV-HER2/neu 
tumor cells were stably infected with hairpins against either a non-targeting control or 
against HUNK.  Cells were then treated with the DNA alkylating (damaging) agent 
adriamycin (doxorubicin) at 4 uM for 0, 30, 60, or 120 minutes and cells were lysed for 
immunoblotting. 
LS174T cells with HUNK knockdown show impaired activation of both ATM 
and CHK2 (Figure 17).  NAF cells with HUNK knockdown show impaired activation of 
ATM.  In both cell lines, HUNK is required to maintain total ATM protein levels after 
DNA damage, as the knockdown cell lines show rapid degradation of ATM in inverse 
proportion to the level of HUNK protein.  CHK2 activation of Cdc25C is impaired in 
LS174T cells with HUNK knockdown, further supporting the interpretation that HUNK 
is required for ATM/CHK2 pathway activation.  HER2 protein stability showed the same 
relationship to HUNK as did ATM, i.e. reduced protein levels after DNA damage in 
HUNK deficient cells. 
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Figure 17.  HUNK may be required for efficient activation of ATM and CHK2 in 
response to DNA damage.  LS174T or NAF cells with stable expression of either 
negative control or anti-HUNK hairpins were treated with 4 uM adriamycin 
(doxorubicin) for the indicated times.  HeLa cells +/- UV treatment used as controls.  
Single experiment. 
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HUNK is does not affect kinase activity of CAMKKβ in vitro. 
To test whether HUNK phosphorylation of CAMKKβ may be physiologically 
relevant, we evaluated the effect of HUNK phosphorylation on CAMKKβ activity as 
measured by phosphorylation of CaMKI.  We generated FLAG-HUNK and FLAG-
CAMKKβ proteins via transient transfection of HEK-293T cells.  Purified GST-CaMKI 
was purchased from Abcam. 
Because GST-CaMKI and FLAG-CAMKKβ migrate at the same electrophoretic 
mobility, we removed the supernatant containing GST-CaMKI from the beads binding 
FLAG-HUNK and FLAG-CAMKKβ after the kinase reaction.  The beads were washed 
and bead and supernatant material were run separately.  We included CaMKI alone as a 
control reaction and confirmed that there was no unprimed autophosphorylation by 
CaMKI in this reaction.  We also included +/- calcium/Calmodulin (gift of Kyle 
Harpole). 
As expected, calcium/Calmodulin increased kinase activity of CAMKKβ (Figure 
18).  There were no HUNK-dependent differences in CAMKKβ activity as measured by 
phosphorylation of GST-CaMKI, suggesting that HUNK does not regulate kinase activity 
or substrate interaction of CAMKKβ.  It is still possible that HUNK regulates another 
aspect of CAMKKβ such as protein stability or localization, but that possibility has yet to 
be investigated. 
It is interesting to note that CAMKKβ phosphorylated HUNK in this experiment, 
with the difference between HUNK phosphorylation +/- CAMKKβ-WT was greater than 
the difference between HUNK-WT and HUNK-K91M autophosphorylation.  This 
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suggests the possibility that CAMKKβ regulates HUNK which, if true, would also make 
possible regulation of HUNK by cellular calcium flux. 
 
HUNK and CAMKKβ are phosphorylated by HUNK, CAMKKβ, and LKB1 at 
multiple sites. 
To identify sites at which HUNK and CAMKKβ are phosphorylated we 
performed IP kinase assays using [γ-18O4]-ATP (Cambridge Isotope Laboratories, >94% 
18O on γ-phosphate).  FLAG-CAMKKβ was generated via transient transfection of HEK-
293T cells, FLAG-HA-mHUNK was generated via stable infection of NAF cells, and 
LKB1/MO25/STRAD was purchased (SIGMA-ALDRICH).  After the reaction was run, 
beads were washed to remove LKB1 heterotrimer, beads were boiled in 1.5X RSB.  
Samples were run on a PAGE gel, the gel was Coomassie stained, and bands were cut out 
as indicated (Figure 19).  Bands were sent to the Taplin Mass Spectrometry Facility at the 
Harvard Medical School for analysis.  Bands were subjected to independent tryptic and 
chymotryptic digests, and peptides analyzed by tandem mass spectrometry.  The 
isotopically labeled ATP used in the kinase assay allowed us to distinguish between 
phosphates deposited before and during the kinase assay. 
The T-Loop had coverage in the chymotryptic digests and was not found to be 
phosphorylated in this experiment.  Numerous other phosphorylations were found in the 
tryptic digests and assigned to the kinase(s) that could have deposited them (Table 4).  
Phosphosites were distributed throughout the protein with no clear pattern of sequence 
P a g e  | 79 
 
 
preference beyond serine and threonine.  It is probably that repeating this assay with 
greater protein input would yield increased coverage and additional phosphosites. 
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Figure 18.  HUNK does not affect activity of CAMKKβ in vitro.  HUNK and 
CAMKKβ were expressed by transient transfection of HEK-293T cells and 
immunoprecipitated onto anti-FLAG antibody conjugated magnetic beads for a kinase 
assay using [γ-32P]-ATP.  After kinase assay, supernatant with GST-CaMKI was 
removed and run separately.  (A) Immunoblot to determine protein loading after batch IP 
for beads used in IP kinase assay.  (B) Autoradiographs from IP kinase assay.  Data are 
representative of more than three experiments, each performed without replicate 
reactions. 
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Figure 19.  MSMS identification of sites in HUNK and CAMKKβ phosphorylated 
by HUNK, CAMKKβ, and LKB1.  Immunoprecipitation kinase assay using [γ-18O4]-
ATP to isotopically label sites phosphorylated during the assay so they could be 
identified via tandem mass spectrometry.  (A) Coomassie stained gel with band cut sites 
indicated.  (B) Identity, quantity, and percent amino acid coverage of bands submitted for 
MSMS phosphosite identification.  Single experiment. 
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HUNK 
phosphorylated 
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HUNK HUNK                 
CAMKKβ
HUNK                      
CAMKKβ                     
LKB1
                                           
CAMKKβ .                          
LKB1
CAMKKβ 
phosphorylated 
by
HUNK HUNK                 
CAMKKβ
HUNK                      
CAMKKβ                     
LKB1
                                           
CAMKKβ .                          
LKB1
S65 S346 T102 T287 S678 S27 S23 S510 S44 T463
S72 T352 T105 S290 S105 S90 S512 S51 S504
S299 S470 T291 S344 S113 S112 T519 S111
S393 S516 T403 T426 S128 S115 T146
S398 S544 S421 S463 S198 S149 T363
S490 S546 T424 S588 S335 S153
T507 S600 T473 T618 S341 T167
S508 S605 S497 S359 S346
S510 S607 S584 S496 T348
S515 S608 T351
S517 S609 T448
S564 S617 S481
S588 S621 T484
S692 S690 T490
S700 S523
S701 S526
S703
HUNK 
phosphorylated 
at
CAMKKβ 
phosphorylated 
at
 
Table 4.  MSMS identification of sites in HUNK and CAMKKβ phosphorylated by 
HUNK, CAMKKβ, and LKB1.   
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DISCUSSION 
We have purified HUNK and used this material to search for substrates via kinase 
assays on protein microarrays.  The protein microarray kinase assay using ATPγS and 
immunofluorescence enabled generation of a ranked list of candidate substrates of 
HUNK kinase, two of which have been verified using immunoprecipitation kinase assays 
(IPKAs) using [γ-32P]-ATP.  We have also uncovered evidence that HUNK regulation of 
the DNA damage response is physiologically relevant in at least two cell lines, with the 
possibility that HUNK phosphorylation of CHK2 is involved. 
The use of the IPKA to confirm 2 of the 19 candidate substrates of HUNK 
supports the idea that other substrates can be found on that list.  It is also possible that 
repeats of the kinase assay on protein microarrays with greater amounts of protein or 
more active protein would augment the list of candidate substrates of HUNK.  It is 
noteworthy that 3 of the 19 substrates of HUNK are found in the MAPK pathway 
(MAP3K13, MAP4K5, MAPKAPK5). 
HUNK phosphorylation of CHK2 led us to evaluate activation of ATM and 
CHK2 after DNA damage, and we found HUNK dependent regulation of both proteins.  
This suggests that ATM may be another HUNK substrate and this should be 
experimentally evaluated.  Furthermore, it is possible that HUNK regulates other proteins 
involved in response to DNA damage, such as ATR/CHK1, and this too should be 
addressed experimentally.  The mechanism for such regulation is at present entirely 
unknown.  We do not know where HUNK phosphorylates CHK2 or what effect that 
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phosphorylation may have, but it is possible that it could alter CHK2 stability, 
localization, kinase activity, or protein:protein interaction. 
ATM is known to stabilize HER2 protein levels by promoting the interaction 
between HSP90 and HER2, promoting the tumorigenicity of HER2166.  This supports the 
finding that HUNK knockdown, which resulted in reduced ATM protein levels after 
DNA damage, correlates with reduced HER2 protein.  This also suggests one mechanism 
by which HUNK promotes and is required for HER2/neu induced tumorigenesis: the 
stabilization of ATM after DNA damage, resulting in prolonged HER2 signaling during 
cellular DNA damage stress.  HUNK is required for activation of nuclear Akt after DNA 
damage (Jung et. al., submitted), suggesting another possible link with HSP90, which 
binds to and regulates the activity of Akt167,168. 
While HUNK did not alter kinase activity of CAMKKβ in vitro, we did not 
address the effect of CAMKKβ phosphorylation of HUNK.  It is possible that CAMKKβ 
phosphorylates the T-Loop of HUNK as CAMKKβ does for AMPKα79, acting as another 
upstream activating kinase.  CAMKKβ acts as the dominant activator of AMPK in certain 
tissues, resulting most notably in CAMKKβ-AMPK dependent regulation of appetite in 
the hypothalamus169.  Both CAMKKβ and HUNK show highest expression in the 
brain12,170.  If CAMKKβ were to regulate HUNK, it would provide HUNK with 
sensitivity to calcium flux and extend the possibilities for HUNK-dependent phenotypes.  
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS 
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SUMMARY 
 
We have demonstrated that contrary to published predictions, LKB1 activates 
HUNK kinase by phosphorylating a conserved threonine residue (T222) in its T-Loop.  
Our experiments with in vitro translated protein indicate that this reaction requires no 
factors other than HUNK and the LKB1/MO25/STRAD heterotrimer and that HUNK 
likely has some intrinsic activity even in the absence of LKB1 activation.  We also 
described data indicating that while LKB1 can phosphorylate HUNK at residues outside 
of the T-Loop, phosphorylation at these sites does not appear to influence LKB1 
dependent control of the kinase activity of HUNK.  Crucially, we showed that LKB1 
controls HUNK activity in vivo as LKB1 overexpression activated HUNK, expression of 
dominant negative LKB1-D194A reduced HUNK activity, and shRNA against LKB1 
lowered HUNK activity. 
Our data show that HUNK binds to LKB1 heterotrimers containing STRADβ but 
not STRADα, raising important questions about the role of compartmentalization in the 
regulation of both HUNK and LKB1. 
We also purified HUNK and used that material in a kinase assay on a protein 
microarray.  We were able to generate a ranked list of candidate substrates of HUNK, 
including the first two substrates identified, CAMKKβ and CHK2.  Following up on the 
identification of CHK2 as a substrate of HUNK, we’ve shown that HUNK is required in 
some cell lines for efficient activation of the ATM/CHK2 pathway in response to DNA 
damage, in part by regulating the stability of both ATM and HER2 after DNA damage.  
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FUTURE DIRECTIONS – HUNK AND LKB1 
 
Does STRAD isoform impact HUNK activation in vivo? 
We found that WT HUNK binds to LKB1, MO25, and STRADβ but not 
STRADα (Figure 9).  This suggests the possibility that HUNK is activated preferentially 
by complexes of LKB1 that contain STRADβ but not STRADα.  We know that HUNK 
can be activated in vitro by LKB1 complexes that contain STRADα because the purified 
recombinant LKB1 heterotrimer we used in our IPKAs (immunoprecipitation kinase 
assays) contained only STRADα.  However, it is possible that in living cells, HUNK is 
preferentially activated by complexes with STRADβ.  
One method for evaluating this would be to knockdown, via either siRNA or 
shRNA, each isoform of STRAD.  If HUNK is preferentially activated by STRADβ, then 
knockdown of the β but not the α isoform of STRAD should reduce the activity of 
HUNK from those cells as evaluated by IP kinase assay. 
 
How does HUNK bind to the LKB1 heterotrimer? 
Questions remain regarding the mode of interaction between HUNK and the 
LKB1 heterotrimer.  Does HUNK bind directly to one or more members of 
LKB1/MO25/STRAD?  Our current data is most consistent with the idea that HUNK 
binds directly to STRADβ.  For the kinase assay in figure 16, HUNK was incubated with 
purified recombinant LKB1/MO25α/STRADα for 30 minutes, after which the 
supernatant with LKB1 heterotrimer was removed and the beads were washed.  Equal 
P a g e  | 88 
 
 
amounts of GST-STRAD remained on the beads to which HUNK-WT, HUNK-K91M, 
and Empty Vector control lysate were immunoprecipitated, suggesting that under those 
conditions, LKB1/MO25α/STRADα did not bind to HUNK.  However, a better way to 
determine binding would be to design an experiment specifically to address the question. 
Using in vitro translated protein, we can generate HA-tagged LKB1, MO25, 
STRADα, STRADβ alone, then incubate with FLAG-HUNK bound to anti-FLAG 
antibody conjugated beads.  This would allow us to determine whether HUNK binds 
directly to a single member of the LKB1 heterotrimer.  To further understand how 
HUNK binds to the LKB1 heterotrimer, we could repeat the co-immunoprecipitation 
experiment as it was performed in figure 9 but using truncation mutants or short segments 
of FLAG-HUNK instead of full-length protein.  We have such expression vectors in lab.  
With the region of binding identified, we can perform alanine scanning mutagenesis to 
find point mutants that abrogate binding, which would represent possible disease states in 
which HUNK activity would be reduced.  
 
Is nuclear localization required for HUNK activation? 
WT HUNK is both nuclear and cytoplasmic while K91M HUNK is excluded 
from the nucleus159.  WT HUNK binds exclusively to LKB1 heterotrimers containing 
STRADβ (Figure 9), which are predominantly nuclear (Figure 1B)51, while K91M 
HUNK only very weakly binds LKB1 heterotrimer components.  If binding to the LKB1 
heterotrimer increases the efficiency of HUNK activation, then nuclear localization 
would be required for full activation of HUNK by LKB1.  We can test the requirement 
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for nuclear localization in HUNK activation by creating a fusion of HUNK with 
ubiquitin, which forces HUNK cytoplasmic localization (unpublished observation), and 
comparing the activity of cytoplasmic HUNK-ubiquitin to that of WT HUNK.  We can 
also test the converse, i.e. whether forcing nuclear localization of K91M HUNK 
promotes interaction with STRADβ containing LKB1 heterotrimers or increases LKB1 
phosphorylation of T222 by fusing K91M HUNK with the 3XSV40 large tag NLS 
(nuclear localization sequence). 
 
Does HUNK alter the nuclear/cytoplasmic distribution of LKB1? 
The orphan nuclear receptor Nur77 binds to nuclear LKB1, increasing its 
nuclear/cytoplasmic ratio and reducing AMPK activation.  WT HUNK binds to LKB1 
complexes containing the primarily nuclear STRADβ.  This suggests the possibility that 
HUNK binding stabilizes LKB1 in the nucleus, shifting its nuclear/cytoplasmic ratio and 
reducing AMPK activation.  LKB1 nuclear/cytoplasmic ratio can most directly be 
evaluated by cellular fractionation, wherein cytoplasmic proteins and nuclear proteins can 
be immunoblotted separately.  If modulation of HUNK levels via either overexpression 
or knockdown leads to an altered nuclear/cytoplasmic ratio of LKB1 in a given cell line, 
then it is possible that AMPK activation will be altered as well.  AMPK activation can be 
evaluated by treating the cells with known activators such as the AMP mimetic AICAR 
(5‑aminoimidazole‑4-carboxamide‑1‑β‑d-ribofuranoside) or the biguanide phenformin 
and blotting for activated AMPK and at least one of its substrates such as ACC (Acetyl 
Coenzyme A Carboxylase)171.  
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FUTURE DIRECTIONS – SEARCHING FOR AND VALIDATING HUNK 
SUBSTRATES 
 
Does CAMKKβ regulate HUNK? 
Our data show much greater phosphate deposited on HUNK in reactions with WT 
CAMKKβ as compared to K194A (kinase dead) CAMKKβ, indicating that CAMKKβ 
phosphorylates HUNK.  CAMKKβ phosphorylates AMPKα at the same conserved 
threonine phosphorylated by LKB1, activating AMPK and providing sensitivity to 
calcium flux in certain tissues169,172,173.  It may be that CAMKKβ phosphorylates the 
conserved threonine in HUNK (T222) to activate HUNK in the same manner as LKB1.  
We plan to test this using a kinase assay similar to that shown in figure 18.  We will co-IP 
FLAG-HUNK, FLAG-CAMKKβ, and a fragment of FLAG-CHK2 (this fragment 
migrates at different apparent molecular weight than other components of this reaction) 
onto anti-FLAG antibody conjugated magnetic beads and then perform a kinase assay 
using [γ-32P]-ATP.  If CAMKKβ phosphorylation of HUNK increases its kinase activity, 
there should be greater phosphate deposited on the FLAG-CHK2 fragment when it is co-
immunoprecipitated with both WT HUNK and WT CAMKKβ.  If CAMKKβ 
phosphorylates and activates HUNK, it will provide a means to link HUNK activity to 
calcium flux. 
If CAMKKβ phosphorylates HUNK at other sites, it may or may not be 
physiologically significant, as for instance the non-T-Loop sites at which LKB1 
phosphorlyates HUNK have no demonstrated biological role.  It is possible that 
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CAMKKβ phosphorylation of HUNK at non-T-Loop sites could regulate other aspects of 
HUNK biology such as protein stability, localization, or interaction with other proteins.  
Each of these could be assessed in cells by both overexpression and knockdown of 
CAMKKβ followed by an experiment in the modified cells.  Altered HUNK protein 
stability can be determined by using cycloheximide to block translation of new HUNK 
and evaluating the quantity of HUNK present in cellular lysate over time.  As HUNK is 
rapidly degraded in response to a wide variety of cellular stresses (data not shown), it 
would be important to include at least one of these stresses (ER stress induced by 
thapsigargin) in this experiment to find out whether CAMKKβ alters HUNK stability 
after stress in the same way that HUNK alters ATM and HER2 stability after DNA 
damage.  Altered localization could be detected by either cell fractionation or 
immunofluorescence.  Altered protein binding of HUNK would be detected by co-
immunoprecipitation assays and 14-3-3 and USP9X should be evaluated as they are 
binding partners of ARKs whose interaction is known to be regulated by 
phosphoryation88,90. 
 
Where does HUNK phosphorylate CHK2 and CAMKKβ? 
We plan to perform additional kinase assays to localize sites where HUNK 
phosphorylates CHK2 and CAMKKβ, now using soluble protein and [γ-18O4]-ATP.  We 
anticipate improved coverage and preservation of phosphorylation for two reasons: 
higher input protein amounts and avoiding the need to elute protein from beads used in 
the IP kinase assays, achieved by boiling in our former workflow174.  We have developed 
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a system for rapid expression and purification of large quantities of protein in sf9 insect 
cells using the pFastBac vector as a starting point.  WT HUNK protein produced in this 
fashion is kinase active and that activity can be raised by LKB1 (data not shown).  
Producing substrate proteins in this fashion, or in bacteria, will rapidly produce 
significantly more protein than that obtained via transient expression in HEK-293T 
cells175.  The use of [γ-18O4]-ATP allows us to once again identify phosphates deposited 
during our kinase reaction.  We plan to generate a ranked list of candidate sites and 
confirm by evaluating phosphorylation of mutants in which the candidate site has been 
mutated to alanine. 
Should the above method for identification of phosphosites fail, we plan to move 
to an approach published in 2010.  This method uses ATPγS to thiophosphorylate 
substrates, the substrates are digested, and thiophosphorylated peptides are covalently 
captured onto disulfide resin and then released using base hydrolysis (NaOH) before 
being identified by mass spectrometry176. 
  
What other candidate HUNK substrates can be verified? 
Table 3 lists 17 untested candidate substrates of HUNK.  Knowledge of kinase 
substrates is vital to understanding kinase biology, and with 2 substrates on the list 
already confirmed, there is no better place to continue searching for HUNK substrates 
than on this list. 
By score, BAZ2B (bromodomain adjacent to zinc finger domain, 2B) is the most 
likely candidate on the list.  It is an understudied member of the bromodomain family of 
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proteins which are involved in regulation of transcription through control of chromatin 
remodeling.  The second strongest untested candidate by score is another understudied 
protein involved in chromatin remodeling, PHF23 (plant homeodomain finger protein 
23).  Also on the candidate list is RTF1, another chromatin remodeling protein177.  A 
connection can be made between these three proteins as HUNK expression is higher in 
poorly differentiated tumors of the colon and ovaries6, poorly differentiated tumor cells 
very often have an expression profile with significant overlap with embryonic stem 
cells178, and stem cell self-renewal is controlled in party by chromatin remodeling 
proteins179.  It is possible that HUNK could promote an expression profile similar to stem 
cells by control of these two chromatin remodeling factors. 
There are also three proteins from the MAPK pathway (MAP3K13, MAP4K5, 
MAPKAPK5), two proteins required for DNA damage repair (CHK2, POLB), and a total 
of eight kinases.  With two proteins confirmed by IP kinase assay, we plan to continue 
evaluating these candidates by generating the protein in house using transient transfection 
of HEK-293T cells and subjecting them to the IPKA.  Each of the kinases on the list will 
first need to be mutationally inactivated to reduce background signal from 
autophosphorylation. 
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FUTURE DIRECTIONS – HUNK, ATM/CHK2, AND THE DNA DAMAGE 
RESPONSE 
 
Does HUNK regulate ATM and CHK2? 
We initially identified CHK2 as a candidate substrate of HUNK using a kinase 
assay on a protein microarray (ProtoArray).  We subsequently confirmed HUNK 
phosphorylation of CHK2 in an immunoprecipitation kinase assay using kinase dead 
CHK2-K249R.  As an initial investigation into whether HUNK phosphorylation of CHK2 
has physiological relevance, we asked whether DNA damage induced activation of 
ATM/CHK2 was altered in cells expressing shRNA against HUNK.  We stably infected 
both LS174T human colon carcinoma and NAF murine MMTV-neu each with control 
non-targeting hairpin and two different hairpins against HUNK.  We treated these cells 
with the DNA alkylating agent Adriamycin and immunoblotted to evaluate activation of 
the ATM/CHK2 pathway.  In the HUNK deficient cell lines treated with Adriamycin, we 
saw impaired activation of both ATM and CHK2, as well as reduced stability of both 
ATM and HER2, suggesting that HUNK is required both for efficient activation of 
ATM/CHK2 and for maintenance of ATM and HER2 protein levels in response to DNA 
damage. 
These data lead to two broad questions.  First, we plan to assay other cell lines, 
tissues, and patient samples to ask in what contexts HUNK regulates DNA damage 
induced ATM/CHK2 activation and protein stability.  The set of cells with which we plan 
to begin this investigation is a subset of the ATCC (American Type Culture Collection) 
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Breast Cancer Cell Panel, from which we have generated several cell lines with HUNK 
levels altered either by shRNA knockdown or overexpression.  We may find that HUNK 
regulates ATM/CHK2 only in certain breast cancer subtypes or in cell lines driven by 
particular oncogenes, knowledge important for the potential therapeutic application of 
this discovery. 
Second, how does HUNK control ATM/CHK2?  As discussed in chapter 3, the 
answer begins with learning where HUNK phosphorylates CHK2, which may suggest the 
mode of regulation as many phosphosites in CHK2 have known effects180.  We also must 
investigate whether HUNK phosphorylates ATM by generating a kinase dead variant and 
using it as a substrate in a kinase assay with HUNK WT and K91M.  The data we already 
have suggests postulation of a mechanism by which HUNK could regulate ATM, HER2, 
and Akt. 
ATM stabilizes HER2 protein levels by promoting the interaction between HSP90 
and HER2, prolonging HER2 signaling and promoting the tumorigenicity of HER2166.  If 
HUNK plays a role in the stabilization of HER2 by ATM and HSP90, this would provide 
a mechanism to explain how HUNK is required for HER2/neu induced mammary 
tumorigenesis7.  HSP90 is also a possible link between HUNK and Akt.  HUNK is 
required for activation of nuclear Akt after DNA damage (Jung et. al., submitted), and 
Akt, like HER2, binds to and is regulated by HSP90167,168.   These three phenotypes could 
each be explained by HUNK regulation of the interaction of HSP90 with its client 
proteins, and other phenotypes would be predicted by this finding. 
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We plan to analyze HUNK regulation of DNA damage induced activation of 
ATM/CHK2 by with immunoblots for pathway activation after DNA damage induced by 
both Adriamycin and γ-IR.  We also plan to examine the efficiency of homologous 
recombination in HUNK deficient and WT cells using a GFP reporter based assay in 
which GFP expression follows HR-directed repair of a double strand break induced by 
transient transfection of the I-SceI endonuclease181.   
 
Does HUNK regulate the  DNA Damage Response? 
We have preliminary data indicating a requirement for HUNK in one DNA repair 
pathway, but almost no data on whether HUNK is involved in other DNA repair 
pathways.  One hint that HUNK might be comes from the list of candidate substrates 
(Table 3), which contains POLB (DNA Polymerase Beta), a DNA polymerase involved 
in base excision and repair.  However, there are a number of experiments that can 
illuminate HUNK’s role in the DNA damage response. 
Does HUNK localization alter after DNA damage?  After DNA damage, many 
DNA damage response proteins exhibit punctate nuclear staining, colocalize with γ-
H2AX, and co-immunoprecipitate with DDR proteins182.  If HUNK does so, this is 
evidence of involvement in the DNA damage response.  We plan to evaluate these factors 
in HEK-293T cells and in U2OS cells, two cell lines commonly used in experiments on 
the DDR.  We plan to modify their HUNK expression, in U2OS cells with shRNA 
against HUNK or non-targeting negative control and HEK-293T cells with transient 
overexpression of either WT or K91M HUNK as well as empty vector control.  We’ll 
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treat cells with Adriamcyin or γ-IR before evaluating HUNK localization and co-
localization by immunofluorescence.  We also plan to evaluate HUNK binding by 
immunoprecipitation assays before and after DNA damage, with particular focus on 
whether HUNK binds to ATM, CHK2, or components of the MRN complex, a primary 
sensor of DNA double strand breaks183. 
We also plan to confirm HUNK regulation of the DDR by examining the kinetics 
of DNA repair in cells.  Our first experiments will again use U2OS and HEK-293T with 
modified HUNK expression.  We plan to use two common assays for the measurement of 
DNA repair kinetics.  First is the comet tail assay, also known as single cell gel 
electrophoresis, which can give a single broad measurement that integrates multiple 
forms of DNA damage for each cell in the assay184,185.  Second is the counting of γ-
H2AX foci via immunofluorescence.  γ-H2AX foci form in response to DNA double 
strand breaks and disappear as DNA is repaired186,187.  With these two measurements, we 
will gain insight into the requirement of HUNK for efficient repair of DNA damage.  
Several independent labs have proven that LKB1 regulates repair of multiple forms of 
DNA damage induced by γ-IR136, UV illumination141, and H2O2142.  Our prediction is 
that HUNK mediates at least a fraction of the LKB1 dependent repair of DNA damage 
and this will lead to a measurable defect in DNA damage repair in HUNK deficient cells 
and may accelerate DNA repair kinetics in cells overexpressing HUNK.  It will also be 
important to assess whether HUNK regulates the activation of the ATR/CHK1 DNA 
repair pathway, the second major pathway for cellular repair of DNA double strand 
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breaks.  This can be evaluated by treating these cells with DNA damage agents and 
blotting for the activated forms of ATR and CHK1. 
To highlight the physiological relevance of HUNK, we will measure cell cycle 
arrest and survival after DNA damage in cells deficient for HUNK.  Cells that fail to 
repair DNA damage eventually undergo cell cycle arrest and/or apoptosis188.  A 
consequence of the prediction that HUNK is required for efficient repair of DNA damage 
is that cells deficient for HUNK would be more likely to undergo DNA damage induced 
cell cycle arrest or apoptosis.  We can measure these two parameters by well established 
methods.  Cell cycle arrest due to DNA damage leads to an increase in cells with 4N 
DNA content as they arrest at the G2/M checkpoint.  This increase in DNA per cell can 
be quantified by flow cytometry after staining cells with propidium iodide.  The 
propidium iodide assessment of cell cycle can be multiplexed with staining with 
fluorescently labeled annexin V to detect apoptosis, allowing a single experiment to 
quantify both cell cycle arrest and apoptosis at the level of the single cell189. 
If HUNK deficient cells are deficient in DNA damage repair, we predict they will 
be more sensitive to therapies that  induce DNA damage, in particular PARP (poly (ADP-
ribose) polymerase) inhibitors136.  This can be measured in several ways, and we plan to 
assess this sensitivity treating cells with the PARP inhibitor 6(5H)-phenanthridinone 
(PHEN) before assessing cell viability using trypan blue exclusion and our automated cell 
counter, the Vi-Cell (Beckman-Coulter). 
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FUTURE DIRECTIONS – HUNK AND TGFβ 
 
Does HUNK regulate TGF-β signaling? 
As discussed in chapter 2, there are data to suggest that LKB1 regulates TGF-β 
signaling via effectors that have yet to be determined.  The gastrointestinal tracts of mice 
deficient for stromal LKB1 form polyps indistinguishable from PJS polyps156.  While 
LKB1-/- stromal cells exhibit unperturbed mTOR, AMPK, SRF, RhoA, and FAK 
signaling157, they produce less TGF-β, a defect which results in increased proliferation of 
epithelial cells in both murine and human PJS tissues158.  As both HUNK and TGF-β 
have been shown to down-regulate MYC expression and lead to inhibition of CDKs8,154, 
it is intriguing to speculate that HUNK may play a role in mediating the relationship 
between LKB1 and TGF-β signaling. 
As an initial investigation, we could treat cells with altered HUNK expression 
with TGF-β1 and examine pathway activation via immunoblot for phospho-SMAD3.  As 
Li et. al. have shown, cells engineered to alter expression levels of LKB1 show an inverse 
correlation between LKB1 expression levels and TGF-β1 induced activation of 
SMAD3190.  As a control for cells with altered HUNK expression, cells with altered 
LKB1 expression should be used in the experiment as this will allow us to determine 
what fraction of the phenotypic effect is mediated by HUNK.  Should this work reveal 
HUNK dependent regulation of TGF-β, further investigation will follow.  
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OVERALL CONCLUSIONS 
Previous publications from our lab have demonstrated that HUNK plays a role in 
the development and progression of cancer in multiple contexts.  HUNK is required for 
tumorigenesis in murine models of breast cancer driven by HER2/neu overexpression or 
by PTEN deletion7,8.  HUNK is also required for metastasis of tumors driven by c-MYC6.  
While the precise molecular mechanisms controlling HUNK-dependent phenotypes are 
unknown, several mechanistic details are known.  HUNK suppresses apoptosis in mouse 
models of cancer driven by HER2/neu overexpression or PTEN deletion7,8, in the former 
by negative regulation of p27kip1 expression and nuclear localization and in the latter by 
negative regulation of c-Myc expression.  HUNK also promotes survival in the involuting 
mammary gland.   
To better understand HUNK dependent phenotypes, we investigated the activation 
of HUNK.  We proved that LKB1 activates HUNK by phosphorylating a conserved 
threonine (T222), and demonstrated that this is sufficient and required for HUNK 
activation in vitro and in vivo.  This finding indicates that HUNK is an effector kinase for 
LKB1, suggesting that HUNK may control LKB1 dependent regulation of DNA damage 
repair or TGF-β signaling, both phenotypes for which mechanisms are incompletely 
understood. 
To gain insight into the molecular mechanisms that underlie HUNK dependent 
phenotypes, we searched for substrates of HUNK using a kinase assay on a protein 
microarray.  We highlighted 19 candidate substrates of HUNK and the first two 
substrates from that list to be tested, CHK2 and CAMKKβ, have been confirmed in 
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immunoprecipitation kinase assays.  We have preliminary data to suggest that HUNK 
phosphorylation of CHK2 is physiologically significant as cells in which HUNK has been 
silenced by shRNA are deficient for activation of ATM/CHK2 in response to DNA 
damage.  We plan to test additional substrates of HUNK from our candidate list, which 
includes three candidates linked to regulation of stem cell differentiation through 
structural regulation of chromatin and three candidates from the MAPK pathway. 
In summary, we propose that HUNK is an LKB1 effector kinase.  The activation 
of HUNK by LKB1 is likely to be required for HUNK mediated anti-apoptotic and pro-
migratory effects in tumors driven by overexpression of HER2/neu and c-Myc and by 
deletion of PTEN.  Further, it is possible that HUNK controls or contributes to multiple 
LKB1-dependent phenotypes.  In particular, the current understanding of LKB1 
dependent regulation of the DNA damage response is incomplete.  Given our preliminary 
data that HUNK phosphorylates CHK2 and, in some contexts, is required for activation 
of the ATM/CHK2 pathway, it is likely that inhibition of HUNK will prove a useful 
therapeutic strategy that can synergize with existing therapies designed to promote DNA 
damage such as PARP inhibitors and standard platinum based chemotherapeutic agents. 
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